<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:bpax="http://www.biosantepharma.com/20130118" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="bpax-20130118.xsd" />
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-10-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_ConvertibleSeniorNotes3.125PercentDue2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_MoneyMarketFundsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q4_M1231_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-12-30</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_MoneyMarketFundsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M1014_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-13</xbrli:startDate>
      <xbrli:endDate>2009-10-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_CapitalAdditionsMember_AptarPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:AptarPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CapitalAdditionsMember_AptarPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:AptarPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0312_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-10-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M02_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_CommonStockMember_LC">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_AntaresPharmaIncLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bpax:AntaresPharmaIncLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M0131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-30</xbrli:startDate>
      <xbrli:endDate>2012-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009Q4_M1014_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-10-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_SoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_NoncomputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bpax:NoncomputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M10_ConvertibleNotesPayableMember_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-15</xbrli:startDate>
      <xbrli:endDate>2009-10-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0131_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M0131_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-30</xbrli:startDate>
      <xbrli:endDate>2012-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-13</xbrli:startDate>
      <xbrli:endDate>2009-10-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-13</xbrli:startDate>
      <xbrli:endDate>2009-10-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_EquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_AntaresPharmaIncLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bpax:AntaresPharmaIncLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_AntaresPharmaIncLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bpax:AntaresPharmaIncLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q1_M02_AntaresPharmaIncLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bpax:AntaresPharmaIncLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_WakeForestLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bpax:WakeForestLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_Plan2008Member_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bpax:Plan2008Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_Plan1998Member_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bpax:Plan1998Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_Plan1998Member_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bpax:Plan1998Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_StockOptionsMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_StockOptionsMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q2_M0623_CommonStockMember_ClassOfWarrantIssuedOn23June2010Due9June2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn23June2010Due9June2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_StockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_StockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_StockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_StockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_StockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_StockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ConvertibleSeniorNotes3.125PercentDue2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_ConvertibleSeniorNotes3.125PercentDue2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_ConvertibleSeniorNotes3.125PercentDue2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bpax:ConvertibleSeniorNotes3.125PercentDue2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-10-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-04-01</xbrli:startDate>
      <xbrli:endDate>2010-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-07-01</xbrli:startDate>
      <xbrli:endDate>2010-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-10-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_M0802_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-08-01</xbrli:startDate>
      <xbrli:endDate>2011-08-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_M0802_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_M0308_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-07</xbrli:startDate>
      <xbrli:endDate>2011-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0308_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2011Due8March2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2011Due8March2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2011Due9June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2011Due9June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q1_M0308_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-03-07</xbrli:startDate>
      <xbrli:endDate>2010-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q1_M0308_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2010Due8September2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2010Due8September2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2010Due9June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2010Due9June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q2_M0623_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-06-22</xbrli:startDate>
      <xbrli:endDate>2010-06-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q2_M0623_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q2_M0623_CommonStockMember_ClassOfWarrantIssuedOn23June2010Due23June2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn23June2010Due23June2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_CommonStockMember_ClassOfWarrantIssuedOn30December2010Due30December2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn30December2010Due30December2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_CommonStockMember_ClassOfWarrantIssuedOn30December2010Due9June2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn30December2010Due9June2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009Q4_M1031_CommonStockMember_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M10_CommonStockMember_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn15December2008Due14June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn15December2008Due14June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn21July2009Due20July2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn21July2009Due20July2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn13August2009Due12August2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn13August2009Due12August2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn13August2009Due9June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn13August2009Due9June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn14October2009Due1April2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn14October2009Due1April2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn8March2010Due8September2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2010Due8September2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn8March2010Due9June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2010Due9June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn23June2010Due23June2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn23June2010Due23June2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn23June2010Due9June2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn23June2010Due9June2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn22November2010Due21November2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn22November2010Due21November2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn30December2010Due30December2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn30December2010Due30December2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn30December2010Due9June2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn30December2010Due9June2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn8March2011Due8March2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2011Due8March2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClassOfWarrantIssuedOn8March2011Due9June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:ClassOfWarrantIssuedOn8March2011Due9June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_CommonStockMember_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_UndesignatedPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bpax:UndesignatedPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009Q4_M1014_ConvertibleNotesPayableMember_CellGenesysIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bpax:CellGenesysIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-10-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0601_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0601_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_StockOptionsMember_SB">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_FairValueInputsLevel2Member_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M02_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M05_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-05-01</xbrli:startDate>
      <xbrli:endDate>2012-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M05_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-05-01</xbrli:startDate>
      <xbrli:endDate>2012-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_CapitalAdditionsMember_AptarPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:AptarPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CapitalAdditionsMember_AptarPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:AptarPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_MergerAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MinimumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:VotingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:VotingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:LockUpAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:LockUpAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M07_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0731_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0229_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M08_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:WarrantIssuedToInstitutionalInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>
      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M08_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>
      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0831_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0831_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:WarrantIssuedToInstitutionalInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0920_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-19</xbrli:startDate>
      <xbrli:endDate>2012-09-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012_ANIPharmaceuticalsIncMember_EmployeeSeveranceMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0924_ShareholderDerivativeActionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">bpax:ShareholderDerivativeActionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-23</xbrli:startDate>
      <xbrli:endDate>2012-09-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_MinimumMember_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Vaccine">
    <xbrli:measure>bpax:vaccine</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Holder">
    <xbrli:measure>bpax:holder</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>bpax:item</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2011" unitRef="USD">57225234</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent decimals="0" contextRef="I2011" unitRef="USD">801147</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent decimals="0" contextRef="I2011" unitRef="USD">58026381</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet decimals="0" contextRef="I2011" unitRef="USD">861364</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:LongTermInvestments decimals="0" contextRef="I2011" unitRef="USD">3405807</us-gaap:LongTermInvestments>
  <us-gaap:DepositsAssetsNoncurrent decimals="0" contextRef="I2011" unitRef="USD">86203</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Assets decimals="0" contextRef="I2011" unitRef="USD">62379755</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent decimals="0" contextRef="I2011" unitRef="USD">3150677</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent decimals="0" contextRef="I2011" unitRef="USD">1597329</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent decimals="0" contextRef="I2011" unitRef="USD">2479697</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent decimals="0" contextRef="I2011" unitRef="USD">7227703</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable decimals="0" contextRef="I2011" unitRef="USD">17336760</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:Liabilities decimals="0" contextRef="I2011" unitRef="USD">24564463</us-gaap:Liabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit decimals="0" contextRef="I2011" unitRef="USD">-217239148</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:LiabilitiesAndStockholdersEquity decimals="0" contextRef="I2011" unitRef="USD">31713052</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LicensesRevenue decimals="0" contextRef="D2011" unitRef="USD">100000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue decimals="0" contextRef="D2010" unitRef="USD">115807</us-gaap:LicensesRevenue>
  <us-gaap:RevenueFromGrants decimals="0" contextRef="D2010" unitRef="USD">51870</us-gaap:RevenueFromGrants>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2011_CommonClassCMember" unitRef="USD">391</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2011_CommonStockMember" unitRef="USD">224387346</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2010_CommonStockMember" unitRef="USD">154110672</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2010_CommonClassCMember" unitRef="USD">391</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2011" unitRef="USD">224387737</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2010_CommonClassCMember" unitRef="Shares">65214</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2010_CommonStockMember" unitRef="Shares">13565188</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding decimals="INF" contextRef="I2010_CommonClassCMember" unitRef="Shares">65214</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding decimals="INF" contextRef="I2010_CommonStockMember" unitRef="Shares">13565188</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">32442</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="D2010_CommonStockMember" unitRef="USD">2014</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="D2011" unitRef="USD">32442</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="D2010" unitRef="USD">2014</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <bpax:StockIssuedDuringPeriodValueWarrantsExercised decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">24062</bpax:StockIssuedDuringPeriodValueWarrantsExercised>
  <bpax:StockIssuedDuringPeriodValueWarrantsExercised decimals="0" contextRef="D2011" unitRef="USD">24062</bpax:StockIssuedDuringPeriodValueWarrantsExercised>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage decimals="INF" contextRef="I2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="Pure">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">1177683</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition decimals="0" contextRef="D2011" unitRef="USD">1177683</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition decimals="0" contextRef="D2010_CommonStockMember" unitRef="USD">992757</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition decimals="0" contextRef="D2010" unitRef="USD">992757</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition decimals="0" contextRef="D2009_CommonStockMember" unitRef="USD">1254503</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition decimals="0" contextRef="D2009" unitRef="USD">1254503</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:ShareBasedCompensation decimals="0" contextRef="D2011" unitRef="USD">1177683</us-gaap:ShareBasedCompensation>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 decimals="2" contextRef="I2011_CellGenesysIncMember" unitRef="USDPerShare">22.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued decimals="0" contextRef="D2011" unitRef="USD">204980</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued decimals="0" contextRef="D2010_CommonStockMember" unitRef="USD">65529</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued decimals="0" contextRef="D2010" unitRef="USD">65529</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued decimals="0" contextRef="D2009_CommonStockMember" unitRef="USD">64103</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued decimals="0" contextRef="D2009" unitRef="USD">64103</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">23876370</bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants>
  <us-gaap:ShareBasedCompensation decimals="0" contextRef="D2010" unitRef="USD">992757</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation decimals="0" contextRef="D2009" unitRef="USD">1254503</us-gaap:ShareBasedCompensation>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims decimals="0" contextRef="D2011" unitRef="USD">204980</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims decimals="0" contextRef="D2010" unitRef="USD">65529</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims decimals="0" contextRef="D2009" unitRef="USD">64103</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment decimals="0" contextRef="D2011" unitRef="USD">-367502</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment decimals="0" contextRef="D2010" unitRef="USD">-4583</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:OtherNoncashIncomeExpense decimals="0" contextRef="D2010" unitRef="USD">65807</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense decimals="0" contextRef="D2009" unitRef="USD">-60739</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="D2011" unitRef="USD">-1682466</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="D2010" unitRef="USD">365332</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="D2009" unitRef="USD">30263</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="D2011" unitRef="USD">134103</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="D2010" unitRef="USD">3142078</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:RevenueFromGrants decimals="0" contextRef="D2009" unitRef="USD">116389</us-gaap:RevenueFromGrants>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2010" unitRef="USD">38155251</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2008" unitRef="USD">11760920</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="D2009" unitRef="USD">-1548535</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NatureOfOperations contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;1. DESCRIPTION OF BUSINESS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;BioSante Pharmaceuticals,&amp;#160;Inc. (the Company) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. The Company's products, either approved or in human clinical development, include: (1)&amp;#160;LibiGel, once daily transdermal testosterone gel in Phase&amp;#160;III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2)&amp;#160;a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA,&amp;#160;Inc. (Teva); (3)&amp;#160;GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and are currently in 17 Phase&amp;#160;I and Phase&amp;#160;II clinical trials for the treatment of various cancers; (4)&amp;#160;The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase&amp;#160;II development; and (5)&amp;#160;Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Jazz Pharmaceuticals,&amp;#160;Inc. (Jazz Pharmaceuticals), our licensee. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's lead product in development has been LibiGel for the treatment of FSD, specifically HSDD, in postmenopausal women, for which there is no FDA-approved pharmaceutical product. The Company continues to analyze the data from the two pivotal LibiGel Phase&amp;#160;III efficacy trials first reported on December&amp;#160;14, 2011. Initial analysis of the efficacy data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences from placebo, results indicated that LibiGel performed as predicted based on previous experience with testosterone products for FSD. However, the placebo response in the two efficacy trials was overwhelming and unpredictable; and therefore, LibiGel's results were not shown to be statistically different from placebo. The LibiGel Phase&amp;#160;III safety study, which completed enrollment in June 2011, continues and will continue during further analysis of the LibiGel efficacy data and until a final strategic decision has been made. It is the Company's objective to meet with the FDA to determine the best path forward, and to make a decision during the second quarter of 2012 whether to continue the LibiGel Phase&amp;#160;III safety study. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's corporate strategy always has included product development of high value medically-needed pharmaceutical products. In light of recently announced top-line results from the Company's two pivotal LibiGel Phase&amp;#160;III efficacy trials, the Company is assessing its corporate strategy. The Company is determining LibiGel's path forward and potential alternative strategies to utilize the continuing LibiGel Phase&amp;#160;III cardiovascular events and breast cancer safety study. The Company also has expanded its efforts to explore new product development projects through in-licensing and mergers and acquisitions. In addition, a full review of the Company's GVAX cancer vaccine portfolio is underway. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On January&amp;#160;31, 2012, the Company received a notice from the Listing Qualifications Department of The NASDAQ Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Global Market under NASDAQ Listing Rule&amp;#160;5450(a)(1). The notification letter stated that pursuant to NASDAQ Listing Rule&amp;#160;5810(c)(3)(A), the Company will be afforded 180 calendar days, or until July&amp;#160;30, 2012, to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the Company's common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by July&amp;#160;30, 2012, the Company may transfer its common stock listing to The NASDAQ Capital Market and be eligible for an additional 180-day grace period if the Company meets the market value of publicly held shares requirement for continued listing and all other initial inclusion requirements for listing on The NASDAQ Capital Market, other than the minimum bid price requirement. In order to be afforded the additional 180-day compliance period, the Company also would need to provide NASDAQ written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not indicate its intent to cure the deficiency or if it does not appear to NASDAQ that it is possible for the Company to cure the deficiency, the Company will not be eligible for the second 180-day grace period and its common stock will be subject to delisting, which delisting determination the Company may appeal to a hearings panel at that time. &lt;/font&gt;&lt;/p&gt;
</us-gaap:NatureOfOperations>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;4. ACQUISITION OF NET ASSETS OF CELL GENESYS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On October&amp;#160;14, 2009, the Company acquired 100&amp;#160;percent of the common stock of Cell Genesys in a direct merger transaction. The merger was accounted as an acquisition of the net assets of Cell Genesys, whereby the individual assets and liabilities of Cell Genesys were recorded by the Company as of the completion of the merger based on their estimated fair values. As Cell Genesys had ceased substantially its operations prior to the date of the transaction, the merger was not considered to be a business combination, and the allocation of the purchase price did not result in recognition of goodwill. The total purchase price is allocated to the acquired assets and assumed liabilities of Cell Genesys based on their estimated relative fair values as of the merger closing date. The table below displays the purchase price of the merger. &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Fair value of BioSante common stock issued (3,369,967 shares)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;36,800,043&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Transaction costs of BioSante&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,431,252&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total purchase price&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;39,231,295&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The total purchase price was allocated as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;24,746,346&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Investment in Ceregene&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;3,486,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;In-process research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;9,000,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Receivables, equipment and other assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;293,658&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,777,323&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Convertible senior notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;16,709,580&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total net assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;19,039,101&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In addition to the $24.7&amp;#160;million in cash acquired, the Company obtained, as a result of the merger, the rights to all in-process research and development of Cell Genesys, which included a portfolio of cancer vaccines and other technologies. The $9.0&amp;#160;million value attributed to this portfolio was expensed as of the date of the acquisition as acquired in-process technology, as it was considered to have no alternative future use. The $20.2&amp;#160;million representing the premium of the total value of consideration in excess of fair values of the net assets acquired also was expensed as of the date of the acquisition. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In addition, as a result of the merger, the Company assumed $1.2&amp;#160;million in aggregate principal amount of 3.125% convertible senior notes due November&amp;#160;1, 2011 and $20.8&amp;#160;million in aggregate principal amount of 3.125% convertible senior notes due May&amp;#160;1, 2013 issued by Cell Genesys. As a result of the merger and in accordance with the terms of the indentures governing the 3.125% convertible senior notes due May&amp;#160;1, 2013 as supplemented by supplemental indentures entered into between the Company and the trustees thereunder, such notes became convertible into an aggregate of 931,093 shares of the Company's common stock at a conversion price of $22.32 per share, in each case subject to adjustments for stock dividends, stock splits, and other similar events. For more details see Note&amp;#160;7, "Convertible Senior Notes." &lt;/font&gt;&lt;/p&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
  <bpax:LiquidityAndCapitalResourcesTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;3. LIQUIDITY AND CAPITAL RESOURCES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Substantially all of the Company's revenue to date has been derived from upfront, milestone and royalty payments earned on licensing transactions and from subcontracts. The Company's business operations to date have consisted mostly of licensing and research and development activities and the Company expects this to continue for the immediate future. The Company has not introduced commercially any products. If and when the Company's products for which it has not entered into marketing relationships receive FDA approval, the Company may begin to incur other expenses, including sales and marketing related expenses if it chooses to market the products itself. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During 2011, the Company raised approximately $68.9&amp;#160;million in net proceeds, after deducting placement agent fees, underwriters' discounts, commissions and other offering expenses, through the sale of common stock in an underwritten public offering and common stock and warrants in a registered direct offering, as more fully described in Note&amp;#160;9, "Stockholders' Equity." &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of December&amp;#160;31, 2011, the Company had $57.2&amp;#160;million of cash and cash equivalents. Absent the receipt of any additional licensing income or financing, the Company expects its cash and cash equivalents balance to decrease as the Company continues to use cash to fund its operations, including in particular its LibiGel Phase&amp;#160;III safety study if the Company decides to continue such study. As of March&amp;#160;12, 2012, the Company has $11.8&amp;#160;million in aggregate principal amount of 3.125% convertible senior notes due May&amp;#160;1, 2013 outstanding. In February 2012, the Company issued an aggregate of approximately 1.9&amp;#160;million shares of its common stock to one of the holders of the Company's 3.125% convertible senior notes due May&amp;#160;1, 2013 in exchange for cancellation of $9.0&amp;#160;million in aggregate principal amount of such notes, including accrued and unpaid interest. Assuming the Company continues its LibiGel Phase&amp;#160;III safety study, the Company expects its cash and cash equivalents as of December&amp;#160;31, 2011 to meet its liquidity requirements through mid 2013. If the Company terminates its LibiGel Phase&amp;#160;III safety study and assuming that the Company does so during the second quarter of 2012 and assuming no other corporate product development and activities, the Company expects its cash and cash equivalents to meet its liquidity requirements through late 2014. These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's future capital requirements will depend upon numerous factors, including:&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the progress, timing, cost and results of the Company's preclinical and clinical development programs, including in particular if the Company decides to continue its LibiGel Phase&amp;#160;III safety study; &lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;whether the Company in-licenses additional new products that require further development; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the cost, timing and outcome of regulatory actions with respect to the Company's products; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the Company's ability to obtain value from its current products and technologies and its ability to out-license its products and technologies to third parties for development and commercialization and the terms of such out-licensings; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the Company's ability to acquire or in-license additional new products and technologies and the costs and expenses of such acquisitions or licenses; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the timing and amount of any royalties, milestone or other payments that the Company may receive from or be obligated to pay to current and potential licensors, licensees and other third parties; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the emergence of competing products and technologies, and other adverse market developments; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the perceived, potential and actual commercial success of the Company's products; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the outstanding principal amount of the Company's 3.125% convertible senior notes due May&amp;#160;1, 2013 that are scheduled to mature and become due and payable on May&amp;#160;1, 2013 and the Company's ability to avoid a "fundamental change" or an "event of default" under the indenture governing such notes, which may cause such notes to become due and payable prior to their maturity date on May&amp;#160;1, 2013; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the Company's operating expenses; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the success, progress, timing and costs of the Company's business development efforts to implement business collaborations, licenses and other business combinations or transactions, and the Company's efforts to evaluate various strategic alternatives available with respect to its products and the Company; and &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;the resolution of the Company's pending purported class action litigation. &lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company does not have any existing credit facilities under which the Company could borrow funds. In the event that the Company would require additional working capital to fund future operations, the Company could seek to acquire such funds through additional equity or debt financing arrangements. If the Company raises additional funds by issuing equity securities, the Company's stockholders may experience dilution. Debt financing, if available, may involve covenants restricting the Company's operations or the Company's ability to incur additional debt. There is no assurance that any financing transaction will be available on terms acceptable to the Company, or at all. As an alternative to raising additional financing, the Company may choose to license one or more of its products or technologies to a third party who may finance a portion or all of the continued development and, if approved, commercialization of that licensed product, sell certain assets or rights under the Company's existing license agreements or enter into other business collaborations or combinations, including the possible sale of the Company. In addition, from time to time, the Company may purchase, exchange or restructure its outstanding convertible senior notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer. Such additional purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the Company's available cash and cash equivalents, the Company's liquidity requirements, contractual restrictions and other factors. Such future purchases, exchanges or restructurings could dilute the percentage ownership of the Company's stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of the Company's existing stockholders and/or decrease the Company's cash balance. A significant decrease in the Company's cash balance may impair the Company's ability to execute strategic alternatives or leave the Company without sufficient cash remaining for operations. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The announcement of the results of the Company's LibiGel Phase&amp;#160;III efficacy trials has significantly depressed the trading price of the Company's common stock and if the Company terminates its LibiGel Phase&amp;#160;III safety study, the trading price of the Company's common stock could be depressed further and affect adversely the Company's ability to raise additional capital. The decrease in the trading price of the Company's common stock has resulted in the bid price for the Company's common stock failing to meet the minimum $1.00 per share required for continued inclusion on The NASDAQ Global Market. The Company has until July&amp;#160;30, 2012 to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the Company's common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by July&amp;#160;30, 2012, the Company may transfer its common stock listing to The NASDAQ Capital Market and be eligible for an additional 180-day grace period if the Company meets the market value of publicly held shares requirement for continued listing and all other initial inclusion requirements for listing on The NASDAQ Capital Market, other than the minimum bid price requirement. In order to be afforded the additional 180-day compliance period, the Company also would need to provide NASDAQ written notice of the Company's intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not indicate its intent to cure the deficiency or if it does not appear to NASDAQ that it is possible for the Company to cure the deficiency, the Company will not be eligible for the second 180-day grace period and its common stock will be subject to delisting, which delisting determination the Company may appeal to a hearings panel at that time. A delisting of the Company's common stock from NASDAQ or even the transfer of the Company's common stock listing to The NASDAQ Capital Market could result in further decreases in the trading price of the Company's common stock and, among other things, could harm the Company's ability to raise financing. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In addition, the announcement of the results of the Company's LibiGel Phase&amp;#160;III efficacy trials has resulted in pending purported class action litigation of which the Company, along with its President and Chief Executive Officer, are defendants, which litigation is described in more detail in Note&amp;#160;13, "Commitments and Contingencies". While the Company believes the actions are without merit and intends to defend the actions vigorously, such litigation could divert management's attention, harm the Company's business and/or reputation and result in significant liabilities, as well as harm the Company's ability to raise financing. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company can provide no assurance that additional financing, if needed, will be available on terms favorable to the Company, or at all. This is particularly true if investors are not confident in the future value of the Company, the Company loses the NASDAQ listing of its common stock and/or economic and market conditions deteriorate. If adequate funds are not available or are not available on acceptable terms when the Company needs them, the Company may need to cut its operating costs further or the Company may be forced to explore other strategic alternatives, such as selling or merging the Company or winding down its operations and liquidating the Company. In such case, the Company's stockholders could lose some or all of their investment. &lt;/font&gt;&lt;/p&gt;
</bpax:LiquidityAndCapitalResourcesTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;7. CONVERTIBLE SENIOR NOTES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As a result of the Company's merger with Cell Genesys, the Company assumed liabilities related to two series of convertible senior notes of Cell Genesys&amp;#8212;$1,234,000 aggregate principal amount of 3.125% convertible senior notes due November&amp;#160;1, 2011 (the 2011 Notes) and $20,782,000 aggregate principal amount of 3.125% convertible senior notes due May&amp;#160;1, 2013 (the 2013 Notes and collectively with the 2011 Notes, the Notes). The conversion features of the Notes were adjusted for the exchange ratio used in the merger, as described in Note&amp;#160;9, "Stockholders' Equity." &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Immediately prior to November&amp;#160;1, 2011, the Company repaid in its entirety the outstanding aggregate principal amount of the 2011 Notes and all accrued interest thereon through such date. As of December&amp;#160;31, 2011, the 2013 Notes remained outstanding. In February 2012, the Company issued 1.9&amp;#160;million shares of its common stock to one of the holders of the 2013 Notes in exchange for cancellation of an aggregate of $9.0&amp;#160;million principal amount of such notes, including accrued and unpaid interest. The $11.8&amp;#160;million principal amount of the remaining 2013 Notes are exchangeable at the option of the holder or upon certain specified events into an aggregate of approximately 0.5&amp;#160;million shares of the Company's common stock at a conversion price of $22.32 per share. The 2013 Notes are our general, unsecured obligations, ranking equally with all of the Company's existing and future unsubordinated, unsecured indebtedness and senior in right of payment to any subordinated indebtedness, but are effectively subordinated to all of the Company's existing and future secured indebtedness to the extent of the value of the related security, and structurally subordinated to all existing and future liabilities and other indebtedness of the Company's subsidiaries. The 2013 Notes are subject to repurchase by the Company at each holder's option, if a fundamental change (as defined in the indenture) occurs, at a repurchase price equal to 100&amp;#160;percent of the principal amount of the 2013 Notes, plus accrued and unpaid interest on the repurchase date and are subject to redemption for cash by the Company, in whole or in part, at a redemption price equal to 100&amp;#160;percent of the principal amount of such notes plus accrued and unpaid interest to the redemption date, if the closing price of the Company's common stock has exceeded 150&amp;#160;percent of the conversion price then in effect with respect to such notes for at least 20 trading days in any period of 30 consecutive trading days ending on the trading day prior to the mailing of the notice of redemption. As of December&amp;#160;31, 2011, the 2013 Notes were not eligible for redemption. The indenture governing the 2013 Notes, as supplemented by the supplemental indenture, does not contain any financial covenants and does not restrict the Company from paying dividends, incurring additional debt or issuing or repurchasing the Company's other securities. In addition, the indenture, as supplemented by the supplemental indenture, does not protect the holders of the 2013 Notes in the event of a highly leveraged transaction or a fundamental change of the Company except in certain circumstances specified in the indenture. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;From time to time, the Company may purchase, exchange or restructure its outstanding 2013 Notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer. Such additional purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the Company's available cash and cash equivalents, the Company's liquidity requirements, contractual restrictions and other factors. Such future purchases, exchanges or restructurings could dilute the percentage ownership of the Company's stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of the Company's existing stockholders and/or decrease the Company's cash balance. A significant decrease in the Company's cash balance may impair the Company's ability to execute strategic alternatives or leave the Company without sufficient cash remaining for operations. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has elected to record the Notes at fair value in order to simplify the accounting for the convertible debt, inclusive of the redemption, repurchase and conversion adjustment features which would otherwise require specialized valuation, bifurcation and recognition. Accordingly, the Company has adjusted the carrying value of the Notes to their fair value as of December&amp;#160;31, 2011, with changes in the fair value of the Notes occurring since December&amp;#160;31, 2010, reflected in fair value adjustment in the statements of operations. The fair value of the Notes is based on Level&amp;#160;2 inputs. The recorded fair value of the Notes of an aggregate of $17,336,760 as of December&amp;#160;31, 2011 differs from their total stated principal amount of $20,782,000 by $3,445,240. The recorded value of the Notes of an aggregate of $18,547,333 as of December&amp;#160;31, 2010 differs from their total stated principal amount of $22,016,000 by $3,468,667. The Company recorded fair value adjustments of $(23,427) and $(1,870,916) related to the Notes for the years ended December&amp;#160;31, 2011 and 2010, respectively, to increase its recorded liability and corresponding expense in 2011 and 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;For the year ended December&amp;#160;31, 2010, approximately $184,000 of the fair value adjustment was attributable to the change in instrument specific credit risk. There was no significant change in the fair value of the convertible senior notes due to a change in instrument specific credit risk for the years ended December&amp;#160;31, 2011 or 2009. The change in the aggregate fair value of the Notes due to instrument specific credit risk was estimated by calculating the difference between the December&amp;#160;31, 2010 fair value of the Notes as recorded and what the fair value of the convertible notes would have been on December&amp;#160;31, 2010 if the December&amp;#160;31, 2009 discount rate continued to be used in the calculation. The instrument specific credit risk for the year ended December&amp;#160;31, 2010 has increased the fair value of the Notes as market borrowing rates have decreased for similarly rated companies and are estimated to have decreased for the Company as well, indicating a lower credit spread assuming no significant changes in the risk-free borrowing rate. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company establishes the value the convertible senior notes based upon contractual terms of the notes, as well as certain key assumptions. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The assumptions as of December&amp;#160;31, 2011 were: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2013 Notes &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.19&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The assumptions as of December&amp;#160;31, 2010 were: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2013 Notes &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 Notes &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.82&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;78.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;61.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The discount rate is based on observed yields as of the measurement date for debt securities of entities having a Ca and Caa3 rating for long-term corporate obligations as assigned by Moody's Investors Service. Volatility is based on the historical fluctuations in the Company's stock price for a period of time equal to the remaining time until the debt maturity. The risk-free rate is based on observed yields as of the measurement date of one-year, two-year and three-year U.S. Treasury Bonds. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following table represents the scheduled maturities of required principal payments by year related to the convertible senior notes at December&amp;#160;31, 2011: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;20,782,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;20,782,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;10. STOCK-BASED COMPENSATION &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has two stockholder-approved equity-based compensation plans under which stock options have been granted&amp;#8212;the BioSante Pharmaceuticals,&amp;#160;Inc. Amended and Restated 1998 Stock Plan (1998 Plan) and the BioSante Pharmaceuticals,&amp;#160;Inc. Second Amended and Restated 2008 Stock Incentive Plan (2008 Plan) (collectively, the Plans). The 2008 Plan replaced the 1998 Plan except with respect to options outstanding under the 1998 Plan. As of December&amp;#160;31, 2011, the number of shares of the Company's common stock authorized for issuance under the 2008 Plan, subject to adjustment as provided in the 2008 Plan, was 1,000,000 plus the number of shares subject to options outstanding under the 1998 Plan as of the effective date of the 2008 Plan but only to the extent that such outstanding options are forfeited, expire or otherwise terminate without the issuance of such shares. Of such authorized shares, 3,416 shares had been issued and 587,666 shares were subject to outstanding stock options as of December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding employee stock options generally vest over a period of three or four years and have 10-year contractual terms. Upon exercise of an option, the Company issues new shares of its common stock. From time to time, the Company grants employee stock options that have performance condition-based vesting provisions which result in expense when such performance conditions are probable of being achieved. None of these options were outstanding as of December&amp;#160;31, 2011. The non-cash, stock-based compensation cost that was incurred by the Company in connection with the 1998 Plan and the 2008 Plan was $1,177,683, $992,757 and $1,254,503 for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. No income tax benefit was recognized in the Company's statements of operations for stock-based compensation arrangements due to the Company's net loss position. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The weighted average fair value of the options at the date of grant for options granted during 2011, 2010 and 2009 was $7.32, $6.66 and $6.24 per share, respectively. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="center" width="94"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="18"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="32"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="18"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="32"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected option life (years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;5.5&amp;#160;-&amp;#160;6.25&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;1.175%&amp;#160;-&amp;#160;2.57%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.42&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;69.07%&amp;#160;-&amp;#160;72.16%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;76.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;76.75&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company uses the simplified method to estimate the life of options. The risk-free interest rate used is the yield on a United States Treasury note as of the grant date with a maturity equal to the estimated life of the option. The Company calculated a volatility rate based on the closing price for its common stock at the end of each calendar month as reported by the NASDAQ Global Market. The Company has not in the past issued a cash dividend nor does it have any current plans to do so in the future; and therefore, an expected dividend yield of zero was used. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following table summarizes the stock option compensation expense for employees and non-employees recognized in the Company's statements of operations for each period: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;423,925&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;325,208&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;361,773&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;753,758&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;667,549&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;892,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;1,177,683&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;992,757&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,254,503&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A summary of activity under the Plans during the year ended December&amp;#160;31, 2011 is presented below: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 28pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Options &lt;!-- COMMAND=ADD_SCROPPEDRULE,28pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Option&lt;br /&gt;
Shares &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise Price &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Term &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Outstanding December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;619,572&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;22.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;162,892&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;346,541&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11.40&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,194&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Forfeited or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;56,059&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17.70&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Outstanding December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;906,860&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.97&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Exercisable at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;474,671&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;25.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.40&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Vested or expected to vest at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;879,777&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.95&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;There is no aggregate intrinsic value of the Company's outstanding and exercisable options as of December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of December&amp;#160;31, 2011, there was $2,089,729 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the Plans. The cost is expected to be recognized over a weighted-average period of 2.76&amp;#160;years. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The intrinsic value of options exercised during the year ended December&amp;#160;31, 2011 and 2010 was $22,106 and $974, respectively. The Company did not receive a tax benefit related to the exercise of these options because of its net operating loss position. The total fair value of shares vested during the years ended December&amp;#160;31, 2011, 2010 and 2009 was $667,171, $764,921 and $788,461, respectively. &lt;/font&gt;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;9. STOCKHOLDERS' EQUITY &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Authorized and Outstanding Capital Stock &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is authorized to issue 200,000,000 shares of common stock, $0.0001 par value per share, 4,687,684 shares of class&amp;#160;C special stock, $0.0001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;No shares of preferred stock were outstanding as of December&amp;#160;31, 2011 or 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;There were 65,214 shares of class&amp;#160;C special stock issued and outstanding as of December&amp;#160;31, 2011 and 2010. Each share of class&amp;#160;C special stock entitles its holder to one vote per share. Each share of class&amp;#160;C special stock is exchangeable, at the option of the holder, for one share of the Company's common stock, at an exchange price of $15.00 per share, subject to adjustment upon certain capitalization events. Holders of class&amp;#160;C special stock are not entitled to receive dividends or to participate in the distribution of the Company's assets upon any liquidation, dissolution or winding-up of the Company. The holders of class&amp;#160;C special stock have no cumulative voting, preemptive, subscription, redemption or sinking fund rights. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;There were 18,269,754 and 13,565,188 shares of common stock issued and outstanding as of December&amp;#160;31, 2011 and 2010, respectively. The Company has presented the par values of its common stock and the related additional paid in capital on a combined basis for all periods presented. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Underwritten Public Offering &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On August&amp;#160;2, 2011, the Company completed an underwritten public offering of an aggregate of 2.7&amp;#160;million shares of its common stock at a purchase price of $18.00 per share, resulting in net proceeds of approximately $45.0&amp;#160;million, after underwriters' discounts, commissions and offering expenses. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Registered Direct Offerings &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On March&amp;#160;8, 2011, the Company completed a registered direct offering of 2,033,247 shares of its common stock and warrants to purchase an aggregate of 711,636 shares of its common stock at a purchase price of $12.3678 per share to institutional investors for gross proceeds of $25.1&amp;#160;million. The offering resulted in net proceeds to the Company of $23.9&amp;#160;million, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately and continuing for a period of three years, at an exercise price of $13.50 per share. In connection with the offering, the Company issued the placement agent warrants to purchase an aggregate of 40,665 shares of the Company's common stock at an exercise price of $15.48 per share, which warrants are exercisable immediately and will expire on June&amp;#160;9, 2014. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On March&amp;#160;8, 2010, the Company completed a registered direct offering of an aggregate of 1,734,104 shares of its common stock and warrants to an aggregate of 867,052 shares of its common stock, at a purchase price of $10.38 per share to funds affiliated with two institutional investors resulting in net proceeds to the Company of approximately $17.5&amp;#160;million, after deducting placement agent fees and other offering expenses. The warrants are exercisable beginning on September&amp;#160;9, 2010, have an exercise price of $12.48 per share and will expire on September&amp;#160;8, 2015. In connection with the offering, the Company issued the placement agent warrants to purchase an aggregate of 34,682 shares of the Company's common stock at an exercise price of $12.96 per share, which warrants are exercisable beginning on September&amp;#160;8, 2010 and will expire on June&amp;#160;9, 2014. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On June&amp;#160;23, 2010, the Company completed a registered direct offering of 1,189,061 shares of its common stock and warrants to purchase an aggregate of 594,530 shares of its common stock at a purchase price of $12.615 per share to funds affiliated with certain institutional investors for gross proceeds of $15.0&amp;#160;million. The offering resulted in net proceeds to the Company of approximately $14.1&amp;#160;million, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately, have an exercise price of $14.70 per share and will expire on June&amp;#160;23, 2015. In connection with the offering, the Company issued the placement agent warrants to purchase an aggregate of 35,671 shares of the Company's common stock at an exercise price of $15.78 per share, which warrants are exercisable immediately and will expire on June&amp;#160;9, 2015. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On December&amp;#160;31, 2010, the Company completed a registered direct offering of 1,764,706 shares of its common stock and warrants to purchase an aggregate of 882,353 shares of its common stock at a purchase price of $10.20 per share to funds affiliated with certain institutional investors for gross proceeds of $18.0&amp;#160;million. The offering resulted in net proceeds to the Company of approximately $16.9&amp;#160;million, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately, have an exercise price of $12.00 per share and expire on December&amp;#160;30, 2015. In connection with the offering, the Company issued the placement agent warrants to purchase an aggregate of 52,941 shares of the Company's common stock at an exercise price of $12.75, which warrants are exercisable immediately and will expire on June&amp;#160;9, 2015. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Acquisition of Net Assets of Cell Genesys &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In October 2009, the Company acquired Cell Genesys in a direct merger. As a result of the merger, each share of common stock of Cell Genesys issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive 0.0305 of a share of the Company's common stock. In the aggregate, the Company issued approximately 3.4&amp;#160;million shares of its common stock to former Cell Genesys stockholders in connection with the merger. All options to purchase shares of Cell Genesys common stock, other than certain designated options held by certain of Cell Genesys's former officers (Assumed Options), became fully vested and exercisable until immediately prior to the effective time of the merger. At the effective time of the merger, such unexercised options other than the Assumed Options terminated. The Assumed Options were assumed by the Company and will remain outstanding following the merger, but converted into and became options to purchase shares of the Company's common stock on terms substantially identical to those in effect prior to the merger, except for adjustments to the underlying number of shares and the exercise price based on the 0.0305 exchange ratio. As a result of the merger, the Assumed Options converted into options to purchase an aggregate of 39,071 shares of the Company's common stock at a weighted average exercise price of $118.38 per share. All warrants to purchase shares of Cell Genesys common stock which by their terms survived the merger (Assumed Warrants) were assumed by the Company, but were converted into and became warrants to purchase shares of the Company's common stock on terms substantially identical to those in effect prior to the merger, except for adjustments to the underlying number of shares and the exercise price based on the 0.0305 exchange ratio. As a result of the merger, these Assumed Warrants converted into warrants to purchase an aggregate of 65,874 shares of the Company's common stock at a weighted average exercise price of $235.62 per share. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;For additional discussion regarding the merger with Cell Genesys and the assets and liabilities acquired, see Note&amp;#160;4, "Acquisition of Net Assets of Cell Genesys." &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Convertible Senior Notes &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;See Note&amp;#160;7, "Convertible Senior Notes" for information regarding the convertible senior notes assumed in the Cell Genesys merger. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Warrants &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of December&amp;#160;31, 2011, warrants to purchase an aggregate of 3,794,741 shares of the Company's common stock were outstanding and exercisable as of December&amp;#160;31, 2011: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="58"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="111"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 38pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Issue Date &lt;!-- COMMAND=ADD_SCROPPEDRULE,38pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Number of&lt;br /&gt;
Underlying&lt;br /&gt;
Shares&lt;br /&gt;
Of Common&lt;br /&gt;
Stock &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Per Share&lt;br /&gt;
Exercise Price &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Expiration Date &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;December&amp;#160;15, 2008&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;24.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;14, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;July&amp;#160;21, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;July&amp;#160;20, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;August&amp;#160;13, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;400,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;August&amp;#160;12, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;August&amp;#160;13, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;40,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;October&amp;#160;14, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;65,874&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;235.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;April&amp;#160;1, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;867,052&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.48&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;September&amp;#160;8, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;34,682&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;June&amp;#160;23, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;594,530&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14.70&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;23, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;June&amp;#160;23, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;35,671&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.78&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;November&amp;#160;22, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;November&amp;#160;21, 2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;December&amp;#160;30, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;882,353&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;December&amp;#160;30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;December&amp;#160;30, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;52,941&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.75&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;670,971&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13.50&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;40,665&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.48&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During 2011, the Company issued warrants to purchase an aggregate of 711,636 shares of the Company's common stock in connection with the March 2011 registered direct offering as described above. During 2011, warrants to purchase an aggregate of 1,458 shares of common stock were exercised and warrants to purchase an aggregate of 151,868 shares of the Company's common stock expired unexercised. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During 2010, the Company issued warrants to purchase an aggregate of 2,467,230 shares of the Company's common stock in connection with registered direct offerings as described above, and warrants to purchase 30,000 shares of the Company's common stock as compensation for investor relations services as described below. During 2010, no warrants were exercised and warrants to purchase an aggregate of 127,291 shares of the Company's common stock expired unexercised. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During 2009, the Company issued warrants to purchase an aggregate of 440,000 shares of the Company's common stock in connection with a registered direct offering, warrants to purchase an aggregate of 65,874 shares of the Company's common stock in connection with the Cell Genesys merger, and warrants to purchase 30,000 shares of the Company's common stock as compensation for investor relations services as described below. During 2009, no warrants were exercised and warrants to purchase an aggregate of 89,166 shares of the Company's common stock expired unexercised. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In 2011, 2010 and 2009, the Company issued warrants to purchase 0, 30,000 and 30,000 shares of the Company's common stock, respectively, in consideration for various investor relations services. The warrants became exercisable on a ratable basis over a twelve-month period from the date of grant. The Company uses the Black-Scholes pricing model to value these types of warrants and remeasures the awards each quarter until the measurement date is established. For the years ended December&amp;#160;31, 2011, 2010 and 2009, the Company recorded $204,980, $65,529 and $64,103, respectively, in non-cash general and administrative expense pertaining to consultant warrants. &lt;/font&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;14. FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company accounts for its convertible senior notes and U.S. Treasury money market fund at fair value. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="LIST-STYLE-TYPE: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1:&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&amp;#160;1 inputs. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2:&amp;#160;&amp;#160;&amp;#160;&amp;#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3:&amp;#160;&amp;#160;&amp;#160;&amp;#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&amp;#160;3 inputs. &lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Financial assets and liabilities recorded at fair value on a recurring basis as of December&amp;#160;31, 2011 and 2010 are classified in the table below in one of the three categories described above: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 87.62%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 189px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 41pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,41pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2011 Balance &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Quoted Prices in&lt;br /&gt;
Active Markets&lt;br /&gt;
for Identical&lt;br /&gt;
Assets (Level&amp;#160;1) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs (Level&amp;#160;2) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs (Level&amp;#160;3) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;br /&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 84.94%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 204px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 41pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,41pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2010 Balance &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Quoted Prices in&lt;br /&gt;
Active Markets&lt;br /&gt;
for Identical&lt;br /&gt;
Assets (Level&amp;#160;1) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs (Level&amp;#160;2) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs (Level&amp;#160;3) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2011 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,111,132&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,111,132&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,436,201&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,436,201&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,547,333&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,547,333&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company made an election to record the values of the 2011 Notes and 2013 Notes at fair value with gains and losses related to fluctuations in the value of these financial liabilities recorded in earning immediately pursuant to ASC 825. The fair values of the 2011 Notes and 2013 Notes are estimated based on the risk-free borrowing rate, the volatility of the Company's stock, and the current borrowing rates for similar companies. See Note&amp;#160;7, "Convertible Senior Notes" for more information and disclosures regarding key assumptions used in this fair value determination. &lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <dei:EntityRegistrantName contextRef="D2012Q3YTD">BIOSANTE PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="D2012Q3YTD">0001023024</dei:EntityCentralIndexKey>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">44961137</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="D2011" unitRef="USD">44961137</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants decimals="0" contextRef="D2011" unitRef="USD">23876370</bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants decimals="0" contextRef="D2010_CommonStockMember" unitRef="USD">48452644</bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants decimals="0" contextRef="D2010" unitRef="USD">48452644</bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants>
  <dei:DocumentType contextRef="D2012Q3YTD">S-4</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="D2012Q3YTD">2012-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="D2012Q3YTD">true</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="D2012Q3YTD">Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:RoyaltyRevenue decimals="0" contextRef="D2011" unitRef="USD">335160</us-gaap:RoyaltyRevenue>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">-23427</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">-1870916</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants decimals="0" contextRef="D2009_CommonStockMember" unitRef="USD">11352751</bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants decimals="0" contextRef="D2009" unitRef="USD">11352751</bpax:StockIssuedDuringPeriodValueCommonSharesAndWarrants>
  <bpax:NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation decimals="INF" contextRef="D2011" unitRef="Vaccine">4</bpax:NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation>
  <bpax:LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder decimals="2" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">1.00</bpax:LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder>
  <bpax:LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount decimals="2" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">1.00</bpax:LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount>
  <us-gaap:ProceedsFromSaleOfShortTermInvestments decimals="0" contextRef="D2009" unitRef="USD">3026334</us-gaap:ProceedsFromSaleOfShortTermInvestments>
  <bpax:ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;The assumptions as of December&amp;#160;31, 2011 were: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 85.86%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 30px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2013 Notes &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.19&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The assumptions as of December&amp;#160;31, 2010 were: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 86.01%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 113px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2013 Notes &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 Notes &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.82&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;78.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;61.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</bpax:ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 decimals="2" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USDPerShare">22.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate decimals="4" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.0082</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths decimals="0" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
  <us-gaap:LongTermDebtFairValue decimals="0" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">17336760</us-gaap:LongTermDebtFairValue>
  <us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments decimals="0" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">3445240</us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate decimals="4" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="Pure">0.0029</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate decimals="3" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.787</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate decimals="3" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="Pure">0.610</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate decimals="4" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.0019</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate decimals="3" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.774</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <bpax:FairValueAssumptionsDiscountRate decimals="3" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.185</bpax:FairValueAssumptionsDiscountRate>
  <bpax:LicenseAgreementsDisclosureTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;5. LICENSE AGREEMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Gel Products &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company licensed the technology underlying LibiGel and Elestrin, but not its male testosterone gel, from Antares Pharma,&amp;#160;Inc. (Antares). Under the agreement, Antares granted the Company an exclusive license to certain patents and patent applications covering these gel products, including rights to sublicense, in order to develop and market the products in certain territories. Under the agreement, the Company is required to pay Antares certain development and regulatory milestone payments and royalties based on net sales of any products the Company or any sub-licensee sells incorporating the in-licensed technology. The patents covering the formulations used in these gel products are expected to expire in 2022 and 2028. The Company's male testosterone gel was developed and is fully-owned by the Company and is not covered under the Antares license. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;GVAX Cancer Vaccine Technology &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company owns development and commercialization rights to its GVAX cancer vaccine technology as a result of its transaction with Cell Genesys. The original core patent applications covering the cancer vaccine technology were licensed exclusively to Cell Genesys from Johns Hopkins University and The Whitehead Institute for Biomedical Research in 1992. Rights to additional patents and patent applications were licensed from Johns Hopkins University in 2001. The patents are expected to expire between 2012 and 2026. Under the various agreements, the Company is required to pay Johns Hopkins University and The Whitehead Institute for Biomedical Research certain development and regulatory milestone payments and royalties based on net sales of any products the Company or any sub-licensee sells incorporating the in-licensed technology. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;The Pill Plus &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company licensed the technology underlying its triple component contraceptive, or The Pill Plus, from Wake Forest University Health Sciences and Cedars-Sinai Medical Center. The financial terms of this license include regulatory milestone payments, maintenance payments and royalty payments by the Company if a product incorporating the licensed technology gets approved and subsequently is marketed. The patents covering the technology underlying The Pill Plus are expected to expire in 2016. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Other License Agreements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has entered into several other license agreements in which the Company has out-licensed certain of the rights and technologies the Company has licensed. Under these agreements, the Company typically is entitled to receive royalty payments on any sales of the products and, in some cases, may be entitled to receive certain development and regulatory milestones. &lt;/font&gt;&lt;/p&gt;</bpax:LicenseAgreementsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber decimals="INF" contextRef="I2011_StockOptionsMember" unitRef="Shares">906860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber decimals="INF" contextRef="I2011_StockOptionsMember" unitRef="Shares">474671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber decimals="INF" contextRef="I2011_StockOptionsMember" unitRef="Shares">879777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="D2011">&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 73%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 41pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,41pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2011 Balance &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Quoted Prices in&lt;br /&gt;
Active Markets&lt;br /&gt;
for Identical&lt;br /&gt;
Assets (Level&amp;#160;1) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs (Level&amp;#160;2) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs (Level&amp;#160;3) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,465,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,336,760&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 73%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 41pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,41pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2010 Balance &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Quoted Prices in&lt;br /&gt;
Active Markets&lt;br /&gt;
for Identical&lt;br /&gt;
Assets (Level&amp;#160;1) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs (Level&amp;#160;2) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs (Level&amp;#160;3) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,729,230&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2011 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,111,132&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,111,132&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,436,201&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,436,201&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,547,333&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,547,333&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_MoneyMarketFundsMember" unitRef="USD">21729230</us-gaap:AssetsFairValueDisclosure>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2010Q4_M1231_CommonStockMember" unitRef="Shares">1764706</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;15. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Selected quarterly data for 2011 and 2010 is as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 73%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="65"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;First &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Second &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Third &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Fourth &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Revenue&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;57,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;81,003&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;182,784&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;114,373&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14,864,420&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,116,323&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,500,053&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,701,465&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,593,557&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,989,103&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,675,268&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,723,562&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Licensing expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Operating loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(16,442,921&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,064,942&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,028,207&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(8,340,710&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(17,250,676&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(14,975,231&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(12,733,691&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(6,648,906&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.20&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.72&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 73%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;First &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Second &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Third &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Fourth &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Revenue&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,279,874&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;51,331&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;143,032&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,426,870&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,657,606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,716,091&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,904,935&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,498,252&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,540,200&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,534,417&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,367,491&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Licensing expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;268,750&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Operating loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(8,959,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,240,352&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(11,240,177&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,168,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,540,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,794,351&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(11,589,711&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,271,735&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_MoneyMarketFundsMember" unitRef="USD">21729230</us-gaap:AssetsFairValueDisclosure>
  <bpax:FairValueAssumptionsDiscountRate decimals="3" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.170</bpax:FairValueAssumptionsDiscountRate>
  <bpax:StockIssuedDuringPeriodCommonStockInConnectionWithRegisteredDirectOfferings decimals="INF" contextRef="I2010_CommonStockMember" unitRef="Shares">2467230</bpax:StockIssuedDuringPeriodCommonStockInConnectionWithRegisteredDirectOfferings>
  <us-gaap:ProceedsFromSaleOfProductiveAssets decimals="0" contextRef="D2010" unitRef="USD">3075</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2011_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD">21729230</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2011_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2011_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2011_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure decimals="0" contextRef="I2011_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">17336760</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure decimals="0" contextRef="I2011_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">17336760</us-gaap:LiabilitiesFairValueDisclosure>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">2033247</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals="0" contextRef="D2011" unitRef="USD">719925</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;13. COMMITMENTS AND CONTINGENCIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Antares Pharma,&amp;#160;Inc. License &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's license agreement with Antares Pharma,&amp;#160;Inc. requires the Company to fund the development of the licensed products, make milestone payments and pay royalties on the sales of products related to this license. In 2011, 2010 and 2009, the Company paid or accrued $335,160, $152,228 and $63,749, respectively, to Antares as a result of royalties generated by Elestrin revenues. Pursuant to a separate agreement with Antares and related to the December 2009 license amendment with Azur Pharma International II Limited (now known as Jazz Pharmaceuticals, in light of Jazz Pharmaceuticals' acquisition of Azur), the Company paid Antares an aggregate of $268,750 in February 2010, which is recorded in licensing expense. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Wake Forest License &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In April 2002, the Company exclusively in-licensed from Wake Forest University Health Sciences and Cedars-Sinai Medical Center three issued U.S. patents claiming triple component therapy (the combination use of estrogen plus progestogen plus androgen, e.g.&amp;#160;testosterone) and obtained an option to license the patents for triple component contraception. The financial terms of the license include an upfront payment by the Company in exchange for exclusive rights to the license and regulatory milestone payments, maintenance payments and royalty payments by the Company if a product incorporating the licensed technology gets approved and subsequently marketed. In July 2005, the Company exercised the option for an exclusive license for the three U.S. patents for triple component contraception. The financial terms of this license include an upfront payment, regulatory milestone payments, maintenance payments and royalty payments by the Company if a product incorporating the licensed technology gets approved and subsequently marketed. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Future minimum maintenance payments due under this agreement are as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="60"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 16pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Year &lt;!-- COMMAND=ADD_SCROPPEDRULE,16pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Minimum&lt;br /&gt;
Amount Due &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;40,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Under the terms of the license agreement with the Wake Forest University Health Sciences and Cedars-Sinai Medical Center, the Company has the right to terminate the license at any time. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has agreed to indemnify, hold harmless and defend Wake Forest University Health Sciences and Cedars-Sinai Medical Center against any and all claims, suits, losses, damages, costs, fees and expenses resulting from or arising out of exercise of the license agreement, including but not limited to, any product liability claims. The Company has not recorded any liability in connection with this obligation as no events occurred that would require indemnification. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Aptar Pharma&amp;#8212;Gel Filling Machine &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company currently has a commitment with Aptar Pharma to purchase a gel filling machine for $842,740. As of December&amp;#160;31, 2011, the Company has paid $337,096 resulting in a remaining obligation of $505,644. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Pending Litigation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On February&amp;#160;3, 2012, a purported class action lawsuit was filed in the United States District Court for the Northern District of Illinois under the caption &lt;/font&gt;&lt;font size="2"&gt;&lt;i&gt;Thomas Lauria, on behalf of himself and all others similarly situated v. BioSante Pharmaceuticals,&amp;#160;Inc. and Stephen M. Simes&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt; naming the Company and the Company's President and Chief Executive Officer, Stephen M. Simes, as defendants. The complaint alleges that certain of the Company's disclosures relating to the efficacy of LibiGel and its commercial potential were false and/or misleading and that such false and/or misleading statements had the effect of artificially inflating the price of the Company's securities resulting in violations of Section&amp;#160;10(b) of the Securities Exchange Act of 1934, as amended (Exchange Act), Rule&amp;#160;10b-5 and Section&amp;#160;20(a) of the Exchange Act. A substantially similar complaint was filed in the same court on February&amp;#160;21, 2012. The plaintiffs seek to represent a class of persons who purchased the Company's securities between February&amp;#160;8, 2010 and December&amp;#160;15, 2011, and seek unspecified compensatory damages, equitable and/or injunctive relief, and reasonable costs, expert fees and attorneys' fees on behalf of such purchasers. BioSante believes the actions are without merit and intends to defend the actions vigorously. Additional lawsuits may be filed and, at this time, because the litigation is in its early stages, the Company is unable to predict the outcome of these lawsuits, the possible loss or range of loss, if any, associated with their resolution or any potential effect they may have on BioSante's operations. Failure by the Company to obtain a favorable resolution of the lawsuits, however, could have a material effect on the Company's financial condition, results of operations, cash flows or its operations. &lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2010_CommonStockMember" unitRef="Shares">4687871</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2009_CommonStockMember" unitRef="Shares">1000000</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="D2009_CommonStockMember" unitRef="USD">6133340</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="D2009" unitRef="USD">6133340</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <bpax:FairValueAssumptionsDiscountRate decimals="3" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="Pure">0.170</bpax:FairValueAssumptionsDiscountRate>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions decimals="INF" contextRef="D2009_CommonStockMember" unitRef="Shares">3369967</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <bpax:AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility decimals="0" contextRef="D2009" unitRef="USD">60343</bpax:AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility>
  <us-gaap:RoyaltyRevenue decimals="0" contextRef="D2010" unitRef="USD">2306560</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue decimals="0" contextRef="D2009" unitRef="USD">1141665</us-gaap:RoyaltyRevenue>
  <us-gaap:Revenues decimals="0" contextRef="D2011" unitRef="USD">435160</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="D2010" unitRef="USD">2474237</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="D2009" unitRef="USD">1258054</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals="0" contextRef="D2010" unitRef="USD">63441</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals="0" contextRef="D2009" unitRef="USD">165724</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations decimals="0" contextRef="D2011" unitRef="USD">-719925</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <bpax:ScheduleOfBusinessAcquisitionsByAcquisitionPurchasePriceTableTextBlock contextRef="D2011">&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 87.6%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 121px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Fair value of BioSante common stock issued (3,369,967 shares)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;36,800,043&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Transaction costs of BioSante&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,431,252&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total purchase price&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;39,231,295&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</bpax:ScheduleOfBusinessAcquisitionsByAcquisitionPurchasePriceTableTextBlock>
  <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities decimals="0" contextRef="D2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">184000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
  <us-gaap:ScheduleOfPurchasePriceAllocationTableTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 96.91%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 181px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;24,746,346&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Investment in Ceregene&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;3,486,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;In-process research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;9,000,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Receivables, equipment and other assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;293,658&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,777,323&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Convertible senior notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;16,709,580&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total net assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;19,039,101&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfPurchasePriceAllocationTableTextBlock>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued decimals="INF" contextRef="D2009Q4_M1014_CellGenesysIncMember" unitRef="Shares">3369967</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:LongTermPurchaseCommitmentAmount decimals="0" contextRef="D2011_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">842740</us-gaap:LongTermPurchaseCommitmentAmount>
  <bpax:PurchaseCommitmentCumulativePaymentsToAcquireMachinery decimals="0" contextRef="I2011_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">337096</bpax:PurchaseCommitmentCumulativePaymentsToAcquireMachinery>
  <us-gaap:PurchaseObligation decimals="0" contextRef="I2011_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">505644</us-gaap:PurchaseObligation>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations decimals="0" contextRef="D2010" unitRef="USD">-60366</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo decimals="0" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">20782000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebt decimals="0" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">20782000</us-gaap:LongTermDebt>
  <bpax:NumberOfPhaseIAndPhaseIIClinicalTrials decimals="INF" contextRef="D2011" unitRef="Item">17</bpax:NumberOfPhaseIAndPhaseIIClinicalTrials>
  <bpax:AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility decimals="0" contextRef="D2009_CommonStockMember" unitRef="USD">60343</bpax:AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations decimals="0" contextRef="D2009" unitRef="USD">2860610</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="D2011">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;6. PROPERTY AND EQUIPMENT &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net of accumulated depreciation at December&amp;#160;31, 2011 and 2010 consists of the following: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;520,647&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;417,840&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;388,659&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;163,653&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;378,147&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;500,130&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;1,287,453&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,081,623&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(426,089&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(445,847&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;861,364&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;635,776&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;There was no construction in progress as of December&amp;#160;31, 2011 or December&amp;#160;31, 2010. &lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:DebtInstrumentFaceAmount decimals="-5" contextRef="I2012Q1_M0312_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">11800000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;8. INCOME TAXES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has analyzed its filing positions in all significant federal and state jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. The Company's U.S. and state tax returns remain subject to examination for the year ended 1998 and all subsequent periods due to the availability of tax loss and credit carryforwards. The Company determined there are no uncertain tax positions existing as of December&amp;#160;31, 2011 or 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The components of the Company's net deferred tax asset at December&amp;#160;31, 2011 and 2010 were as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;63,969,813&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;46,071,206&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Tax basis in intangible assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;4,095,269&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,452,360&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred financing costs for tax&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;7,010,462&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,001,619&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research&amp;#160;&amp;amp; development credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;8,266,610&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5,796,148&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Stock option expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;2,754,981&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,310,405&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;448,140&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;25,955&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;86,545,275&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;65,657,693&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(86,545,275&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(65,657,693&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has no current tax provision due to its current and accumulated losses, which result in net operating loss carryforwards. At December&amp;#160;31, 2011, the Company had approximately $169,456,000 of net operating loss carryforwards that are available to reduce future taxable income for a period of up to 20&amp;#160;years. The net operating loss carryforwards expire in the years 2018-2031 and their utilization in future years may be limited as prescribed by Section&amp;#160;382 of the United States Internal Revenue Code. The net operating loss carryforwards as well as amortization of various intangibles, principally acquired in-process research and development, and other items have generated deferred tax benefits, which have been recorded as deferred tax assets and are entirely offset by a tax valuation allowance. The valuation allowance has been provided at 100% to reduce the deferred tax assets to zero, which is the amount management believes is more likely than not to be realized. Additionally, the Company has provided a full valuation allowance against $8,266,610 of research and development credits, which are available to reduce future income taxes, if any in the future. The research and development credits expire in the years 2018-2031. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate of 34.5% to pre-tax income as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Tax at U.S. federal statutory rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(17,804,934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(15,937,695&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(16,397,080&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(1,677,276&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,501,377&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,544,652&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(1,537,863&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(966,941&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(515,235&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;132,491&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;133,932&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,718&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;20,887,582&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,272,081&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,439,249&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;11. RETIREMENT PLAN &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company offers a discretionary 401(k) Plan to all of its employees. Under the 401(k) Plan, employees may defer income on a tax-exempt basis, subject to limitations under the Internal Revenue Code of 1986, as amended. Under the 401(k) Plan, the Company may make discretionary matching contributions. Company contributions expensed in 2011, 2010 and 2009 totaled $211,494, $179,349 and $117,969, respectively. &lt;/font&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;12. LEASE ARRANGEMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has entered into lease commitments for rental of its office space which expires in 2014. The future minimum lease payments during 2012, 2013 and 2014 are $236,747, $248,632 and $41,718, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Rent expense amounted to $424,294, $338,588 and $325,093 for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage decimals="INF" contextRef="I2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="D2011">&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 93.8%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 143px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;63,969,813&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;46,071,206&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Tax basis in intangible assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;4,095,269&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,452,360&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred financing costs for tax&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;7,010,462&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,001,619&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research&amp;#160;&amp;amp; development credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;8,266,610&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5,796,148&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Stock option expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;2,754,981&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,310,405&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;448,140&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;25,955&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;86,545,275&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;65,657,693&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(86,545,275&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(65,657,693&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 91.64%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 76px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Tax at U.S. federal statutory rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(17,804,934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(15,937,695&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(16,397,080&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(1,677,276&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,501,377&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,544,652&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(1,537,863&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(966,941&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(515,235&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;132,491&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;133,932&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,718&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;20,887,582&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,272,081&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,439,249&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 86.16%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 54px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;20,782,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;20,782,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments decimals="0" contextRef="I2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">3468667</us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards decimals="0" contextRef="I2011" unitRef="USD">63969813</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <bpax:NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing decimals="INF" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Item">1</bpax:NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage decimals="INF" contextRef="I2012Q1_M0312_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities decimals="-5" contextRef="D2012Q1_M02_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Shares">1900000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity decimals="-5" contextRef="D2011_CommonStockMember_LC" unitRef="USD">68900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets decimals="0" contextRef="I2011" unitRef="USD">4095269</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011_RetainedEarningsMember" unitRef="USD">-51608504</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2011" unitRef="USD">44182260</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2010" unitRef="USD">39705502</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2009" unitRef="USD">13680573</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2011" unitRef="USD">6981490</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2010" unitRef="USD">5940360</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2009" unitRef="USD">5373945</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentInProcess decimals="0" contextRef="D2009" unitRef="USD">9000000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2010_RetainedEarningsMember" unitRef="USD">-46196216</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2009_RetainedEarningsMember" unitRef="USD">-47527768</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities decimals="0" contextRef="D2009" unitRef="USD">-2431252</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:CashAcquiredFromAcquisition decimals="0" contextRef="D2009" unitRef="USD">24746346</us-gaap:CashAcquiredFromAcquisition>
  <bpax:RepaymentsOfShortTermConvertibleDebt decimals="0" contextRef="D2011" unitRef="USD">1234000</bpax:RepaymentsOfShortTermConvertibleDebt>
  <us-gaap:ProceedsFromStockOptionsExercised decimals="0" contextRef="D2011" unitRef="USD">32442</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised decimals="0" contextRef="D2010" unitRef="USD">2014</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises decimals="0" contextRef="D2011" unitRef="USD">24062</us-gaap:ProceedsFromWarrantExercises>
  <bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering decimals="0" contextRef="D2011" unitRef="USD">44961137</bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="0" contextRef="D2011" unitRef="USD">23876370</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="0" contextRef="D2010" unitRef="USD">48452644</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="0" contextRef="D2009" unitRef="USD">11352751</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2011" unitRef="USD">67660011</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:LongTermDebtFairValue decimals="0" contextRef="I2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">18547333</us-gaap:LongTermDebtFairValue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2010" unitRef="USD">48454658</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2009" unitRef="USD">33667845</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2011" unitRef="USD">19069983</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2010" unitRef="USD">8296786</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2009" unitRef="USD">18097545</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:InterestPaid decimals="0" contextRef="D2011" unitRef="USD">688000</us-gaap:InterestPaid>
  <bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued decimals="INF" contextRef="D2012Q1_M02_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Holder">1</bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued>
  <us-gaap:DebtConversionOriginalDebtAmount1 decimals="-5" contextRef="D2012Q1_M02_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">9000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:RoyaltyExpense decimals="0" contextRef="D2011_AntaresPharmaIncLicenseMember" unitRef="USD">335160</us-gaap:RoyaltyExpense>
  <us-gaap:InterestPaid decimals="0" contextRef="D2010" unitRef="USD">688000</us-gaap:InterestPaid>
  <us-gaap:DebtInstrumentFaceAmount decimals="0" contextRef="I2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">20782000</us-gaap:DebtInstrumentFaceAmount>
  <bpax:NumberOfConsecutiveBusinessDaysForWhichCommonStockBidPriceIsBelowMinimumRequirement contextRef="D2012Q1_M0131">P30D</bpax:NumberOfConsecutiveBusinessDaysForWhichCommonStockBidPriceIsBelowMinimumRequirement>
  <bpax:SharePriceToBeMaintainedForInclusionInGlobalMarket decimals="2" contextRef="I2011_MinimumMember" unitRef="USDPerShare">1.00</bpax:SharePriceToBeMaintainedForInclusionInGlobalMarket>
  <bpax:NumberOfDaysAffordedToRegainComplainceWithMinimumBidPriceRequirement contextRef="D2012Q1_M0131">P180D</bpax:NumberOfDaysAffordedToRegainComplainceWithMinimumBidPriceRequirement>
  <bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors decimals="INF" contextRef="I2010_CommonStockMember" unitRef="Shares">882353</bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors>
  <bpax:AdditionalGracePeriodToRegainComplainceIfStockListingIsTransferredToNASDAQCapitalMarket contextRef="D2012Q1_M0131">P180D</bpax:AdditionalGracePeriodToRegainComplainceIfStockListingIsTransferredToNASDAQCapitalMarket>
  <us-gaap:InterestPaid decimals="0" contextRef="D2009" unitRef="USD">248388</us-gaap:InterestPaid>
  <bpax:NoncashInvestment decimals="0" contextRef="D2010" unitRef="USD">65807</bpax:NoncashInvestment>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;These financial statements are expressed in U.S. dollars. The Company is organized into one operating and one reporting segment. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles). The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company does not have items of other comprehensive income for years ended December&amp;#160;31, 2011, 2010 or 2009; and therefore, has not presented comprehensive income. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On June&amp;#160;1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class&amp;#160;C special stock. All share and per share numbers have been adjusted retroactively to reflect the one-for-six reverse stock split effected on June&amp;#160;1, 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On October&amp;#160;14, 2009, the Company acquired 100&amp;#160;percent of the common stock of Cell Genesys,&amp;#160;Inc. (Cell Genesys) in a direct merger transaction, with the Company being the surviving corporation. The primary reason the Company merged with Cell Genesys was the Company's need for additional funding to continue its Phase&amp;#160;III clinical studies for LibiGel and the lack of other available acceptable alternatives for the Company to access capital prior to and at the time the merger agreement was entered into by the parties in June 2009, especially in light of the then state of the markets for equity offerings, which historically had been the Company's primary method for raising additional financing. Effective October&amp;#160;14, 2009, the balance sheet and net loss of the Company reflect the purchase price allocation and charges resulting from the purchase price allocation related to the merger, which included adjustments to carrying values of the acquired net assets based on their estimated fair values as of that date. &lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Reclassifications &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Certain amounts in the 2010 and 2009 financial statements have been reclassified to conform to their presentation in the 2011 financial statements. Specifically, in the statement of cash flows, the changes related to Accounts receivable in the amounts of $64,645 and $285,838 for the years ended December&amp;#160;31, 2010 and 2009, respectively, have been combined into the Prepaid expenses and other assets line item within the net cash used in operating activities section. &lt;/font&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company generally considers all instruments with original maturities of three months or less to be cash equivalents. Interest income on invested cash balances is recognized on the accrual basis as earned. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of December&amp;#160;31, 2011, all of the Company's cash and cash equivalents resided in a 100&amp;#160;percent FDIC-insured non-interest bearing checking account, a U.S. Treasury money market fund or a certificate of deposit. As of December&amp;#160;31, 2010, all of the Company's cash and cash equivalents resided in a 100&amp;#160;percent FDIC-insured non-interest bearing checking account in order to ensure maximum safety of principal. &lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The carrying value of certain of the Company's financial instruments, including cash equivalents, accounts receivable and accounts payable, approximate fair value due to their short maturities. Other information about the Company's assets and liabilities recorded at fair value is included in Note&amp;#160;14, "Fair Value Measurements." &lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Property and Equipment &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment that currently is being used in the Company's operations is stated at cost less accumulated depreciation and amortization. Depreciation is computed primarily on a straight line basis over the estimated useful lives of the respective assets, typically five and seven years for software and computer equipment and 10&amp;#160;years for non-computer equipment. &lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Long-Lived Assets &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Long-lived assets are reviewed for possible impairment whenever events indicate that the carrying amount of such assets may not be recoverable. If such a review indicates an impairment, the carrying amount of such assets is reduced to estimated recoverable value. &lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Convertible Senior Notes &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company assumed two series of 3.125% convertible senior note obligations with an aggregate principal balance of $22,016,000, which contain certain redemption, repurchase and conversion adjustment features as a result of its transaction with Cell Genesys. The Company made an irrevocable election to account for these convertible senior notes at fair value commencing from the date of the merger, resulting in recognition of a single liability for the convertible senior notes which are reported at fair value at each reporting date. Subsequent changes in the carrying value of the convertible senior notes are reflected in fair value adjustment in the accompanying statements of operations. &lt;/font&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Research and Development &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Research and development costs are charged to expense as incurred. Direct government grants are recorded as an offset to the related research and development costs when the Company has complied with the conditions attached to the grant and there is reasonable assurance that the funds will be received. &lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:LegalCostsPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Legal Costs &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;For ongoing matters, legal costs are charged to expense as incurred. &lt;/font&gt;&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Basic and Diluted Net Loss Per Share &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The basic and diluted net loss per share is computed based on the weighted average number of the shares of common stock and class&amp;#160;C special stock outstanding, all being considered as equivalent of one another. Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of shares outstanding for the reporting period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The computation of diluted loss per share does not include the Company's stock options, warrants or convertible debt as such securities have an antidilutive effect on loss per share. &lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company recognizes stock-based compensation expense granted to employees generally on a straight-line basis over the estimated service period of the award, or when certain performance-based vesting provisions occur, for awards that contain these features. The Company also has granted options to non-employees in exchange for services. Expense related to such grants is recognized within the Company's statements of operations in accordance with the nature of the service received by the Company. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Warrants issued to non-employees as compensation for services rendered are valued at their fair value on the date of issue and are re-measured until the counterparty's performance under the arrangement is complete. &lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has entered into various licensing agreements that have generated license revenue or other upfront fees and which also may involve subsequent milestone payments earned upon completion of development milestones by the Company or upon the occurrence of certain regulatory actions, such as the filing of a regulatory application or the receipt of a regulatory approval. Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured and the Company has no further performance obligations under the license agreement. Non-refundable license fees that meet these criteria and are due to the Company upon execution of an agreement are recognized as revenue immediately. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Milestones, in the form of additional license fees, typically represent non-refundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified clinical development activities and/or regulatory submissions and/or approvals, or as sales-based milestone payments. Revenues from milestone payments that meet the criteria in the preceding paragraph are recognized when the milestone is achieved. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Additionally, royalty revenue based upon sales of products under license is recorded when such royalties are earned and are deemed collectible, which is generally in the quarter when the related products are sold. &lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Income Taxes &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by enacted tax rates. A valuation allowance is provided against deferred income tax assets in circumstances where management believes the recoverability of a portion of the assets is not more likely than not. The Company has provided a full valuation allowance against its net deferred tax assets as of December&amp;#160;31, 2011 and 2010. &lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:CostMethodInvestmentsPolicy contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Investments &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The investments balance of $3,405,807 as of December&amp;#160;31, 2011 and 2010 consists of the Company's investments that are recorded using the cost method, and substantially represents the Company's investment in Ceregene,&amp;#160;Inc., a privately held biotechnology company (Ceregene). As a result of the Company's merger with Cell Genesys, the Company acquired a minority investment in Ceregene. The Company has recorded its investment using the cost method, as no active market exists for this investment, and the Company does not possess significant influence over operating and financial policies of Ceregene, although the Company by virtue of its stock ownership of Ceregene has the right to designate one member on the Ceregene board of directors. During 2010, the Company recorded a $286,000 impairment on this investment. Such impairment was based on a third-party investment in Ceregene in 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The valuation of investments accounted for under the cost method is based on all available financial information related to the investee, including valuations based on recent third party equity investments in the investee. If an unrealized loss on any investment is considered to be other-than-temporary, the loss is recognized in the period the determination is made. All investments are reviewed for changes in circumstances or occurrence of events that suggest the investment may not be recoverable. The fair value of the cost method investments are not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investments and it is not practicable to estimate the fair value of the investments. &lt;/font&gt;&lt;/p&gt;</us-gaap:CostMethodInvestmentsPolicy>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D2011">
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Recent Accounting Pronouncements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&amp;#160;2011-04, "&lt;/font&gt;&lt;font size="2"&gt;&lt;i&gt;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.&amp;#160;GAAP and International Financial Reporting Standards (IFRS)&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;." This pronouncement was issued to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S.&amp;#160;GAAP and IFRS. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for Level&amp;#160;3 fair value measurements. This pronouncement is effective for reporting periods beginning on or after December&amp;#160;15, 2011, with early adoption prohibited. The new guidance will require prospective application. The Company will adopt this guidance at the beginning of its first quarter of 2012. Adoption of this guidance is not expected to have a material impact on the Company's financial position, results of operations or cash flows. &lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments decimals="INF" contextRef="D2011" unitRef="Item">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:NumberOfReportableSegments decimals="INF" contextRef="D2011" unitRef="Item">1</us-gaap:NumberOfReportableSegments>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired decimals="2" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="Pure">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <us-gaap:IncreaseDecreaseInAccountsReceivable decimals="0" contextRef="D2010" unitRef="USD">64645</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable decimals="0" contextRef="D2009" unitRef="USD">285838</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <bpax:FDICInsuredAccountPercentageOfBalanceInsured decimals="2" contextRef="I2011" unitRef="Pure">1.00</bpax:FDICInsuredAccountPercentageOfBalanceInsured>
  <bpax:FDICInsuredAccountPercentageOfBalanceInsured decimals="2" contextRef="I2010" unitRef="Pure">1.00</bpax:FDICInsuredAccountPercentageOfBalanceInsured>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2011_SoftwareMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2011_ComputerEquipmentMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2011_NoncomputerEquipmentMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <bpax:NumberOfSeriesOfConvertibleNotesAssumed decimals="INF" contextRef="D2009Q4_M10_ConvertibleNotesPayableMember_CellGenesysIncMember" unitRef="Item">2</bpax:NumberOfSeriesOfConvertibleNotesAssumed>
  <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 decimals="0" contextRef="D2009Q4_M10_ConvertibleNotesPayableMember_CellGenesysIncMember" unitRef="USD">22016000</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
  <us-gaap:LongTermInvestments decimals="0" contextRef="I2010" unitRef="USD">3405807</us-gaap:LongTermInvestments>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet decimals="0" contextRef="D2010" unitRef="USD">286000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
  <bpax:SharePriceToBeMaintainedForInclusionInGlobalMarket decimals="2" contextRef="I2012Q1_M0131_MinimumMember" unitRef="USDPerShare">1.00</bpax:SharePriceToBeMaintainedForInclusionInGlobalMarket>
  <bpax:NumberOfConsecutiveBusinessDaysToMaintainMinimumBidClosingPrice contextRef="D2012Q1_M0131_MinimumMember">P10D</bpax:NumberOfConsecutiveBusinessDaysToMaintainMinimumBidClosingPrice>
  <bpax:ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock contextRef="D2011">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;These financial statements are expressed in U.S. dollars. The Company is organized into one operating and one reporting segment. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles). The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company does not have items of other comprehensive income for years ended December&amp;#160;31, 2011, 2010 or 2009; and therefore, has not presented comprehensive income. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On June&amp;#160;1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class&amp;#160;C special stock. All share and per share numbers have been adjusted retroactively to reflect the one-for-six reverse stock split effected on June&amp;#160;1, 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On October&amp;#160;14, 2009, the Company acquired 100&amp;#160;percent of the common stock of Cell Genesys,&amp;#160;Inc. (Cell Genesys) in a direct merger transaction, with the Company being the surviving corporation. The primary reason the Company merged with Cell Genesys was the Company's need for additional funding to continue its Phase&amp;#160;III clinical studies for LibiGel and the lack of other available acceptable alternatives for the Company to access capital prior to and at the time the merger agreement was entered into by the parties in June 2009, especially in light of the then state of the markets for equity offerings, which historically had been the Company's primary method for raising additional financing. Effective October&amp;#160;14, 2009, the balance sheet and net loss of the Company reflect the purchase price allocation and charges resulting from the purchase price allocation related to the merger, which included adjustments to carrying values of the acquired net assets based on their estimated fair values as of that date. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Reclassifications &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Certain amounts in the 2010 and 2009 financial statements have been reclassified to conform to their presentation in the 2011 financial statements. Specifically, in the statement of cash flows, the changes related to Accounts receivable in the amounts of $64,645 and $285,838 for the years ended December&amp;#160;31, 2010 and 2009, respectively, have been combined into the Prepaid expenses and other assets line item within the net cash used in operating activities section. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company generally considers all instruments with original maturities of three months or less to be cash equivalents. Interest income on invested cash balances is recognized on the accrual basis as earned. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of December&amp;#160;31, 2011, all of the Company's cash and cash equivalents resided in a 100&amp;#160;percent FDIC-insured non-interest bearing checking account, a U.S. Treasury money market fund or a certificate of deposit. As of December&amp;#160;31, 2010, all of the Company's cash and cash equivalents resided in a 100&amp;#160;percent FDIC-insured non-interest bearing checking account in order to ensure maximum safety of principal. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The carrying value of certain of the Company's financial instruments, including cash equivalents, accounts receivable and accounts payable, approximate fair value due to their short maturities. Other information about the Company's assets and liabilities recorded at fair value is included in Note&amp;#160;14, "Fair Value Measurements." &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Property and Equipment &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment that currently is being used in the Company's operations is stated at cost less accumulated depreciation and amortization. Depreciation is computed primarily on a straight line basis over the estimated useful lives of the respective assets, typically five and seven years for software and computer equipment and 10&amp;#160;years for non-computer equipment. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Long-Lived Assets &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Long-lived assets are reviewed for possible impairment whenever events indicate that the carrying amount of such assets may not be recoverable. If such a review indicates an impairment, the carrying amount of such assets is reduced to estimated recoverable value. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Convertible Senior Notes &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company assumed two series of 3.125% convertible senior note obligations with an aggregate principal balance of $22,016,000, which contain certain redemption, repurchase and conversion adjustment features as a result of its transaction with Cell Genesys. The Company made an irrevocable election to account for these convertible senior notes at fair value commencing from the date of the merger, resulting in recognition of a single liability for the convertible senior notes which are reported at fair value at each reporting date. Subsequent changes in the carrying value of the convertible senior notes are reflected in fair value adjustment in the accompanying statements of operations. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Research and Development &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Research and development costs are charged to expense as incurred. Direct government grants are recorded as an offset to the related research and development costs when the Company has complied with the conditions attached to the grant and there is reasonable assurance that the funds will be received. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Legal Costs &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;For ongoing matters, legal costs are charged to expense as incurred. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Basic and Diluted Net Loss Per Share &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The basic and diluted net loss per share is computed based on the weighted average number of the shares of common stock and class&amp;#160;C special stock outstanding, all being considered as equivalent of one another. Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of shares outstanding for the reporting period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The computation of diluted loss per share does not include the Company's stock options, warrants or convertible debt as such securities have an antidilutive effect on loss per share. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company recognizes stock-based compensation expense granted to employees generally on a straight-line basis over the estimated service period of the award, or when certain performance-based vesting provisions occur, for awards that contain these features. The Company also has granted options to non-employees in exchange for services. Expense related to such grants is recognized within the Company's statements of operations in accordance with the nature of the service received by the Company. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Warrants issued to non-employees as compensation for services rendered are valued at their fair value on the date of issue and are re-measured until the counterparty's performance under the arrangement is complete. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has entered into various licensing agreements that have generated license revenue or other upfront fees and which also may involve subsequent milestone payments earned upon completion of development milestones by the Company or upon the occurrence of certain regulatory actions, such as the filing of a regulatory application or the receipt of a regulatory approval. Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured and the Company has no further performance obligations under the license agreement. Non-refundable license fees that meet these criteria and are due to the Company upon execution of an agreement are recognized as revenue immediately. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Milestones, in the form of additional license fees, typically represent non-refundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified clinical development activities and/or regulatory submissions and/or approvals, or as sales-based milestone payments. Revenues from milestone payments that meet the criteria in the preceding paragraph are recognized when the milestone is achieved. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Additionally, royalty revenue based upon sales of products under license is recorded when such royalties are earned and are deemed collectible, which is generally in the quarter when the related products are sold. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Income Taxes &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by enacted tax rates. A valuation allowance is provided against deferred income tax assets in circumstances where management believes the recoverability of a portion of the assets is not more likely than not. The Company has provided a full valuation allowance against its net deferred tax assets as of December&amp;#160;31, 2011 and 2010. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Investments &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The investments balance of $3,405,807 as of December&amp;#160;31, 2011 and 2010 consists of the Company's investments that are recorded using the cost method, and substantially represents the Company's investment in Ceregene,&amp;#160;Inc., a privately held biotechnology company (Ceregene). As a result of the Company's merger with Cell Genesys, the Company acquired a minority investment in Ceregene. The Company has recorded its investment using the cost method, as no active market exists for this investment, and the Company does not possess significant influence over operating and financial policies of Ceregene, although the Company by virtue of its stock ownership of Ceregene has the right to designate one member on the Ceregene board of directors. During 2010, the Company recorded a $286,000 impairment on this investment. Such impairment was based on a third-party investment in Ceregene in 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The valuation of investments accounted for under the cost method is based on all available financial information related to the investee, including valuations based on recent third party equity investments in the investee. If an unrealized loss on any investment is considered to be other-than-temporary, the loss is recognized in the period the determination is made. All investments are reviewed for changes in circumstances or occurrence of events that suggest the investment may not be recoverable. The fair value of the cost method investments are not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investments and it is not practicable to estimate the fair value of the investments. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Recent Accounting Pronouncements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&amp;#160;2011-04, "&lt;/font&gt;&lt;font size="2"&gt;&lt;i&gt;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.&amp;#160;GAAP and International Financial Reporting Standards (IFRS)&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;." This pronouncement was issued to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S.&amp;#160;GAAP and IFRS. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for Level&amp;#160;3 fair value measurements. This pronouncement is effective for reporting periods beginning on or after December&amp;#160;15, 2011, with early adoption prohibited. The new guidance will require prospective application. The Company will adopt this guidance at the beginning of its first quarter of 2012. Adoption of this guidance is not expected to have a material impact on the Company's financial position, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;</bpax:ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuable decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">36800043</us-gaap:BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuable>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">2431252</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">39231295</us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice>
  <us-gaap:BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">24746346</us-gaap:BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents>
  <us-gaap:DebtInstrumentFaceAmount decimals="0" contextRef="I2010_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">22016000</us-gaap:DebtInstrumentFaceAmount>
  <bpax:BusinessAcquisitionPurchasePriceAllocationInvestments decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">3486000</bpax:BusinessAcquisitionPurchasePriceAllocationInvestments>
  <bpax:BusinessAcquisitionPurchasePriceAllocationInProcessResearchAndDevelopment decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">9000000</bpax:BusinessAcquisitionPurchasePriceAllocationInProcessResearchAndDevelopment>
  <bpax:BusinessAcquisitionPurchasePriceAllocationReceivablesEquipmentAndOtherAssets decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">293658</bpax:BusinessAcquisitionPurchasePriceAllocationReceivablesEquipmentAndOtherAssets>
  <bpax:BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccountsPayableAndAccruedLiabilities decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">1777323</bpax:BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccountsPayableAndAccruedLiabilities>
  <us-gaap:BusinessAcquisitionPurchasePriceAllocationNotesPayableAndLongTermDebt decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">16709580</us-gaap:BusinessAcquisitionPurchasePriceAllocationNotesPayableAndLongTermDebt>
  <us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet decimals="0" contextRef="I2009Q4_M1014_CellGenesysIncMember" unitRef="USD">19039101</us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet>
  <us-gaap:ResearchAndDevelopmentInProcess decimals="-5" contextRef="D2009Q4_M1014_CellGenesysIncMember" unitRef="USD">9000000</us-gaap:ResearchAndDevelopmentInProcess>
  <bpax:ExcessConsiderationPaidOverFairValue decimals="-5" contextRef="D2009Q4_M1014_CellGenesysIncMember" unitRef="USD">20200000</bpax:ExcessConsiderationPaidOverFairValue>
  <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 decimals="0" contextRef="D2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="USD">1234000</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
  <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 decimals="0" contextRef="D2009Q4_M1014_CellGenesysIncMember_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">20782000</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments decimals="INF" contextRef="D2011_CellGenesysIncMember" unitRef="Shares">931093</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 87.3%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 136px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;520,647&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;417,840&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;388,659&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;163,653&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;378,147&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;500,130&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;1,287,453&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,081,623&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;(426,089&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(445,847&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;861,364&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;635,776&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2011_ComputerEquipmentMember" unitRef="USD">520647</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2011_OfficeEquipmentMember" unitRef="USD">388659</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2011_EquipmentMember" unitRef="USD">378147</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2011" unitRef="USD">1287453</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2010_ComputerEquipmentMember" unitRef="USD">417840</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2010_OfficeEquipmentMember" unitRef="USD">163653</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2010_EquipmentMember" unitRef="USD">500130</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross decimals="0" contextRef="I2010" unitRef="USD">1081623</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment decimals="0" contextRef="I2011" unitRef="USD">426089</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment decimals="0" contextRef="I2010" unitRef="USD">445847</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentNet decimals="0" contextRef="I2010" unitRef="USD">635776</us-gaap:PropertyPlantAndEquipmentNet>
  <bpax:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice decimals="2" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Pure">1.50</bpax:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice>
  <bpax:DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member">P20D</bpax:DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
  <bpax:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member">P30D</bpax:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays>
  <bpax:DeferredTaxAssetsDeferredFinancingCosts decimals="0" contextRef="I2011" unitRef="USD">7010462</bpax:DeferredTaxAssetsDeferredFinancingCosts>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment decimals="0" contextRef="I2011" unitRef="USD">8266610</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost decimals="0" contextRef="I2011" unitRef="USD">2754981</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsOther decimals="0" contextRef="I2011" unitRef="USD">448140</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross decimals="0" contextRef="I2011" unitRef="USD">86545275</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments decimals="-5" contextRef="D2011_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="Shares">500000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DeferredTaxAssetsValuationAllowance decimals="0" contextRef="I2011" unitRef="USD">86545275</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards decimals="0" contextRef="I2010" unitRef="USD">46071206</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets decimals="0" contextRef="I2010" unitRef="USD">4452360</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <bpax:DeferredTaxAssetsDeferredFinancingCosts decimals="0" contextRef="I2010" unitRef="USD">7001619</bpax:DeferredTaxAssetsDeferredFinancingCosts>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment decimals="0" contextRef="I2010" unitRef="USD">5796148</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost decimals="0" contextRef="I2010" unitRef="USD">2310405</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsOther decimals="0" contextRef="I2010" unitRef="USD">25955</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross decimals="0" contextRef="I2010" unitRef="USD">65657693</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance decimals="0" contextRef="I2010" unitRef="USD">65657693</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet decimals="0" contextRef="I2011" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:OperatingLossCarryforwards decimals="0" contextRef="I2011" unitRef="USD">169456000</us-gaap:OperatingLossCarryforwards>
  <bpax:OperatingLossCarryforwardsTerm contextRef="D2011_MaximumMember">P20Y</bpax:OperatingLossCarryforwardsTerm>
  <bpax:PercentageOfProvisionOfValuationAllowanceToReduceDeferredTaxAssets decimals="2" contextRef="I2011" unitRef="Pure">1.00</bpax:PercentageOfProvisionOfValuationAllowanceToReduceDeferredTaxAssets>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate decimals="3" contextRef="D2011" unitRef="Pure">0.345</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate decimals="0" contextRef="D2011" unitRef="USD">-17804934</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate decimals="0" contextRef="D2010" unitRef="USD">-15937695</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate decimals="0" contextRef="D2009" unitRef="USD">-16397080</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes decimals="0" contextRef="D2011" unitRef="USD">-1677276</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes decimals="0" contextRef="D2010" unitRef="USD">-1501377</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes decimals="0" contextRef="D2009" unitRef="USD">-1544652</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment decimals="0" contextRef="D2011" unitRef="USD">-1537863</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment decimals="0" contextRef="D2010" unitRef="USD">-966941</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment decimals="0" contextRef="D2009" unitRef="USD">-515235</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments decimals="0" contextRef="D2011" unitRef="USD">132491</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments decimals="0" contextRef="D2010" unitRef="USD">133932</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments decimals="0" contextRef="D2009" unitRef="USD">17718</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance decimals="0" contextRef="D2011" unitRef="USD">20887582</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance decimals="0" contextRef="D2010" unitRef="USD">18272081</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance decimals="0" contextRef="D2009" unitRef="USD">18439249</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2011" unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent decimals="0" contextRef="I2011" unitRef="USD">236747</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears decimals="0" contextRef="I2011" unitRef="USD">248632</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears decimals="0" contextRef="I2011" unitRef="USD">41718</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesRentExpenseNet decimals="0" contextRef="D2011" unitRef="USD">424294</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet decimals="0" contextRef="D2010" unitRef="USD">338588</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet decimals="0" contextRef="D2009" unitRef="USD">325093</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 85.45%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 85px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="60"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 16pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Year &lt;!-- COMMAND=ADD_SCROPPEDRULE,16pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Minimum&lt;br /&gt;
Amount Due &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;40,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;80,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
  <us-gaap:RoyaltyExpense decimals="0" contextRef="D2010_AntaresPharmaIncLicenseMember" unitRef="USD">152228</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense decimals="0" contextRef="D2009_AntaresPharmaIncLicenseMember" unitRef="USD">63749</us-gaap:RoyaltyExpense>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2010Q1_M02_AntaresPharmaIncLicenseMember" unitRef="USD">268750</us-gaap:LicenseCosts>
  <bpax:NumberOfPatentsForWhichOptionForLicenceIsExercised decimals="INF" contextRef="I2011_WakeForestLicenseMember" unitRef="Item">3</bpax:NumberOfPatentsForWhichOptionForLicenceIsExercised>
  <us-gaap:ContractualObligationDueInNextTwelveMonths decimals="0" contextRef="I2011_WakeForestLicenseMember" unitRef="USD">80000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondYear decimals="0" contextRef="I2011_WakeForestLicenseMember" unitRef="USD">80000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInThirdYear decimals="0" contextRef="I2011_WakeForestLicenseMember" unitRef="USD">80000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:ContractualObligationDueInFourthYear decimals="0" contextRef="I2011_WakeForestLicenseMember" unitRef="USD">80000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:ContractualObligationDueInFifthYear decimals="0" contextRef="I2011_WakeForestLicenseMember" unitRef="USD">40000</us-gaap:ContractualObligationDueInFifthYear>
  <us-gaap:ContractualObligationDueAfterFifthYear decimals="0" contextRef="I2011_WakeForestLicenseMember" unitRef="USD">80000</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:DefinedContributionPlanCostRecognized decimals="0" contextRef="D2011" unitRef="USD">211494</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized decimals="0" contextRef="D2010" unitRef="USD">179349</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized decimals="0" contextRef="D2009" unitRef="USD">117969</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent decimals="0" contextRef="I2010" unitRef="USD">2469879</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent decimals="0" contextRef="I2010" unitRef="USD">40625130</us-gaap:AssetsCurrent>
  <us-gaap:DepositsAssetsNoncurrent decimals="0" contextRef="I2010" unitRef="USD">99937</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Assets decimals="0" contextRef="I2010" unitRef="USD">44766650</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent decimals="0" contextRef="I2010" unitRef="USD">4864217</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent decimals="0" contextRef="I2010" unitRef="USD">526022</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent decimals="0" contextRef="I2010" unitRef="USD">1681956</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:SeniorNotesCurrent decimals="0" contextRef="I2010" unitRef="USD">1111132</us-gaap:SeniorNotesCurrent>
  <us-gaap:LiabilitiesCurrent decimals="0" contextRef="I2010" unitRef="USD">8183327</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable decimals="0" contextRef="I2010" unitRef="USD">17436201</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:Liabilities decimals="0" contextRef="I2010" unitRef="USD">25619528</us-gaap:Liabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit decimals="0" contextRef="I2010" unitRef="USD">-165630644</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:LiabilitiesAndStockholdersEquity decimals="0" contextRef="I2010" unitRef="USD">14099947</us-gaap:LiabilitiesAndStockholdersEquity>
  <bpax:ExcessConsiderationPaidOverFairValue decimals="0" contextRef="D2009" unitRef="USD">20192194</bpax:ExcessConsiderationPaidOverFairValue>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2011" unitRef="USD">50000</us-gaap:LicenseCosts>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2010" unitRef="USD">268750</us-gaap:LicenseCosts>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2009" unitRef="USD">299616</us-gaap:LicenseCosts>
  <us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2011" unitRef="USD">148240</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2010" unitRef="USD">167986</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2009" unitRef="USD">137280</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:CostsAndExpenses decimals="0" contextRef="D2011" unitRef="USD">51361990</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses decimals="0" contextRef="D2010" unitRef="USD">46082598</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses decimals="0" contextRef="D2009" unitRef="USD">48683608</us-gaap:CostsAndExpenses>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2011" unitRef="USD">-23427</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2010" unitRef="USD">-1870916</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2009" unitRef="USD">33163</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:InterestExpense decimals="0" contextRef="D2011" unitRef="USD">681573</us-gaap:InterestExpense>
  <us-gaap:InterestExpense decimals="0" contextRef="D2010" unitRef="USD">688083</us-gaap:InterestExpense>
  <us-gaap:InterestExpense decimals="0" contextRef="D2009" unitRef="USD">147025</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncome decimals="0" contextRef="D2011" unitRef="USD">15000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome decimals="0" contextRef="D2010" unitRef="USD">244479</us-gaap:OtherNonoperatingIncome>
  <us-gaap:InvestmentIncomeInterest decimals="0" contextRef="D2011" unitRef="USD">8326</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest decimals="0" contextRef="D2010" unitRef="USD">12665</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest decimals="0" contextRef="D2009" unitRef="USD">11648</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011" unitRef="USD">-51608504</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2010" unitRef="USD">-46196216</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2009" unitRef="USD">-47527768</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasic decimals="2" contextRef="D2011" unitRef="USDPerShare">-3.15</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic decimals="2" contextRef="D2010" unitRef="USDPerShare">-4.21</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic decimals="2" contextRef="D2009" unitRef="USDPerShare">-8.40</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted decimals="2" contextRef="D2011" unitRef="USDPerShare">-3.15</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted decimals="2" contextRef="D2010" unitRef="USDPerShare">-4.21</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted decimals="2" contextRef="D2009" unitRef="USDPerShare">-8.40</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="INF" contextRef="D2011" unitRef="Shares">16397618</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="INF" contextRef="D2010" unitRef="Shares">10985291</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="INF" contextRef="D2009" unitRef="Shares">5658608</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="INF" contextRef="D2011" unitRef="Shares">16397618</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="INF" contextRef="D2010" unitRef="Shares">10985291</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="INF" contextRef="D2009" unitRef="Shares">5658608</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 decimals="0" contextRef="D2009" unitRef="USD">18487298</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
  <us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1 decimals="0" contextRef="D2009" unitRef="USD">3486000</us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1>
  <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 decimals="0" contextRef="D2009" unitRef="USD">293658</us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid decimals="0" contextRef="D2011" unitRef="USD">21405</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2011" unitRef="USD">-47870103</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2010" unitRef="USD">-40097506</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2009" unitRef="USD">-18430910</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2009" unitRef="USD">29858465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockIssued1 decimals="0" contextRef="D2009" unitRef="USD">36800043</us-gaap:StockIssued1>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2008_CommonClassCMember" unitRef="USD">391</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2008_CommonStockMember" unitRef="USD">85732688</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2008_RetainedEarningsMember" unitRef="USD">-71906660</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2008" unitRef="USD">13826419</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2009_CommonClassCMember" unitRef="USD">391</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2009_CommonStockMember" unitRef="USD">104597728</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2009" unitRef="USD">-14836309</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2009_RetainedEarningsMember" unitRef="USD">-119434428</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2010_CommonClassCMember" unitRef="USD">391</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2010_CommonStockMember" unitRef="USD">154110672</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2010_RetainedEarningsMember" unitRef="USD">-165630644</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2010" unitRef="USD">-11519581</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2011_CommonClassCMember" unitRef="USD">391</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2011_CommonStockMember" unitRef="USD">224387346</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2011_RetainedEarningsMember" unitRef="USD">-217239148</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2011" unitRef="USD">7148589</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2008_CommonStockMember" unitRef="Shares">4507127</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2009_CommonStockMember" unitRef="Shares">8877094</us-gaap:CommonStockSharesIssued>
  <bpax:FractionalShareAdjustment decimals="INF" contextRef="D2010_CommonStockMember" unitRef="Shares">1</bpax:FractionalShareAdjustment>
  <bpax:FractionalShareAdjustment decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">1</bpax:FractionalShareAdjustment>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">2666666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 92.89%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 83px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="center" width="94"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="18"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="32"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="18"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="32"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected option life (years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;5.5&amp;#160;-&amp;#160;6.25&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;1.175%&amp;#160;-&amp;#160;2.57%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.42&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;69.07%&amp;#160;-&amp;#160;72.16%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;76.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;76.75&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 91.96%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 78px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;423,925&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;325,208&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;361,773&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;753,758&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;667,549&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;892,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&lt;b&gt;1,177,683&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;992,757&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,254,503&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="D2011">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 88.5%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 80px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 28pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Options &lt;!-- COMMAND=ADD_SCROPPEDRULE,28pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Option&lt;br /&gt;
Shares &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise Price &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Term &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Outstanding December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;619,572&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;22.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;162,892&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;346,541&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11.40&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,194&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Forfeited or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;56,059&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17.70&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Outstanding December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;906,860&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.97&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Exercisable at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;474,671&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;25.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.40&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Vested or expected to vest at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;879,777&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.95&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <bpax:NumberOfStockholderApprovedEquityBasedCompensationPlans decimals="INF" contextRef="I2011" unitRef="Item">2</bpax:NumberOfStockholderApprovedEquityBasedCompensationPlans>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized decimals="INF" contextRef="I2011_Plan2008Member_StockOptionsMember" unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod decimals="INF" contextRef="D2011_Plan1998Member_StockOptionsMember" unitRef="Shares">3416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber decimals="INF" contextRef="I2011_Plan1998Member_StockOptionsMember" unitRef="Shares">587666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2011_StockOptionsMember_MinimumMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2011_StockOptionsMember_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <bpax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualTerm contextRef="D2011_StockOptionsMember">P10Y</bpax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualTerm>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2011_StockOptionsMember" unitRef="USD">1177683</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2010_StockOptionsMember" unitRef="USD">992757</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2009_StockOptionsMember" unitRef="USD">1254503</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue decimals="2" contextRef="D2011_StockOptionsMember" unitRef="USDPerShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue decimals="2" contextRef="D2010_StockOptionsMember" unitRef="USDPerShare">6.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue decimals="2" contextRef="D2009_StockOptionsMember" unitRef="USDPerShare">6.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2011_StockOptionsMember_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2011_StockOptionsMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2010_StockOptionsMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2009_StockOptionsMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum decimals="5" contextRef="D2011_StockOptionsMember" unitRef="Pure">0.01175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum decimals="4" contextRef="D2011_StockOptionsMember" unitRef="Pure">0.0257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum decimals="4" contextRef="D2011_StockOptionsMember" unitRef="Pure">0.6907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum decimals="4" contextRef="D2011_StockOptionsMember" unitRef="Pure">0.7216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate decimals="4" contextRef="D2010_StockOptionsMember" unitRef="Pure">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate decimals="4" contextRef="D2009_StockOptionsMember" unitRef="Pure">0.0274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate decimals="4" contextRef="D2010_StockOptionsMember" unitRef="Pure">0.7605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate decimals="4" contextRef="D2009_StockOptionsMember" unitRef="Pure">0.7675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate decimals="2" contextRef="D2011_StockOptionsMember" unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2010Q2_M0623_CommonStockMember_ClassOfWarrantIssuedOn23June2010Due9June2015Member" unitRef="USDPerShare">15.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2011" unitRef="USD">1177683</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2010" unitRef="USD">992757</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2009" unitRef="USD">1254503</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2011_StockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">423925</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2010_StockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">325208</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2009_StockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">361773</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2011_StockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">753758</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2010_StockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">667549</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense decimals="0" contextRef="D2009_StockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">892730</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber decimals="INF" contextRef="I2010_StockOptionsMember" unitRef="Shares">619572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross decimals="INF" contextRef="D2011_StockOptionsMember" unitRef="Shares">346541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised decimals="INF" contextRef="D2011_StockOptionsMember" unitRef="Shares">3194</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod decimals="INF" contextRef="D2011_StockOptionsMember" unitRef="Shares">56059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice decimals="2" contextRef="I2010_StockOptionsMember" unitRef="USDPerShare">22.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice decimals="2" contextRef="I2011_StockOptionsMember" unitRef="USDPerShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice decimals="2" contextRef="D2011_StockOptionsMember" unitRef="USDPerShare">11.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice decimals="2" contextRef="D2011_StockOptionsMember" unitRef="USDPerShare">10.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice decimals="2" contextRef="D2011_StockOptionsMember" unitRef="USDPerShare">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice decimals="2" contextRef="I2011_StockOptionsMember" unitRef="USDPerShare">25.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice decimals="2" contextRef="I2011_StockOptionsMember" unitRef="USDPerShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2010_StockOptionsMember">P6Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2011_StockOptionsMember">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="D2011_StockOptionsMember">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="D2011_StockOptionsMember">P6Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue decimals="0" contextRef="I2010_StockOptionsMember" unitRef="USD">162892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue decimals="0" contextRef="I2011_StockOptionsMember" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 decimals="0" contextRef="I2011_StockOptionsMember" unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue decimals="0" contextRef="I2011_StockOptionsMember" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions decimals="0" contextRef="I2011_StockOptionsMember" unitRef="USD">2089729</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2011_StockOptionsMember">P2Y9M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue decimals="0" contextRef="D2011_StockOptionsMember" unitRef="USD">22106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue decimals="0" contextRef="D2010_StockOptionsMember" unitRef="USD">974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue decimals="0" contextRef="D2011_StockOptionsMember" unitRef="USD">667171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue decimals="0" contextRef="D2010_StockOptionsMember" unitRef="USD">764921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue decimals="0" contextRef="D2009_StockOptionsMember" unitRef="USD">788461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member" unitRef="USD">21729230</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="D2011">&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 73%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="65"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;First &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Second &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Third &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Fourth &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Revenue&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;57,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;81,003&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;182,784&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;114,373&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14,864,420&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,116,323&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,500,053&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,701,465&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,593,557&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,989,103&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,675,268&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,723,562&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Licensing expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Operating loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(16,442,921&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,064,942&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,028,207&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(8,340,710&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(17,250,676&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(14,975,231&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(12,733,691&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(6,648,906&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.20&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.72&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 73%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="72"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;First &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Second &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Third &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Fourth &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Revenue&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,279,874&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;51,331&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;143,032&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,426,870&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,657,606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,716,091&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,904,935&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,498,252&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,540,200&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,534,417&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,367,491&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Licensing expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;268,750&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Operating loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(8,959,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,240,352&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(11,240,177&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,168,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,540,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,794,351&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(11,589,711&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(13,271,735&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:Revenues decimals="0" contextRef="D2011Q1" unitRef="USD">57000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2011Q1" unitRef="USD">14864420</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2011_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">17336760</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2011_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">17336760</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="USD">1111132</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2011Q1" unitRef="USD">1593557</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_ConvertibleSeniorNotes3.125PercentDue2011Member" unitRef="USD">1111132</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2011Q1" unitRef="USD">0</us-gaap:LicenseCosts>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">17436201</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2011Q1" unitRef="USD">-16442921</us-gaap:OperatingIncomeLoss>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member_ConvertibleSeniorNotes3.125PercentDue2013Member" unitRef="USD">17436201</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011Q1" unitRef="USD">-17250676</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:LiabilitiesFairValueDisclosure decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD">18547333</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure decimals="0" contextRef="I2010_FairValueMeasurementsRecurringMember_FairValueInputsLevel2Member" unitRef="USD">18547333</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2011Q1" unitRef="USDPerShare">-1.20</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2011Q2" unitRef="USDPerShare">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2011Q3" unitRef="USDPerShare">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2011Q4" unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues decimals="0" contextRef="D2011Q2" unitRef="USD">81003</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2011Q2" unitRef="USD">11116323</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2011Q2" unitRef="USD">1989103</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2011Q2" unitRef="USD">0</us-gaap:LicenseCosts>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2011Q2" unitRef="USD">-13064942</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011Q2" unitRef="USD">-14975231</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:Revenues decimals="0" contextRef="D2011Q3" unitRef="USD">182784</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2011Q3" unitRef="USD">11500053</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2011Q3" unitRef="USD">1675268</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2011Q3" unitRef="USD">50000</us-gaap:LicenseCosts>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2011Q3" unitRef="USD">-13028207</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011Q3" unitRef="USD">-12733691</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:Revenues decimals="0" contextRef="D2011Q4" unitRef="USD">114373</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2011Q4" unitRef="USD">6701465</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2011Q4" unitRef="USD">1723562</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2011Q4" unitRef="USD">0</us-gaap:LicenseCosts>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2011Q4" unitRef="USD">-8340710</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011Q4" unitRef="USD">-6648906</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:Revenues decimals="0" contextRef="D2010Q1" unitRef="USD">2279874</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2010Q1" unitRef="USD">9426870</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2010Q1" unitRef="USD">1498252</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2010Q1" unitRef="USD">268750</us-gaap:LicenseCosts>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2010Q1" unitRef="USD">-8959419</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2010Q1" unitRef="USD">-10540419</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2010Q1" unitRef="USDPerShare">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2010Q2" unitRef="USD">8657606</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2010Q2" unitRef="USD">1540200</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2010Q2" unitRef="USD">-10240352</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2010Q2" unitRef="USD">-10794351</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2010Q2" unitRef="USDPerShare">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues decimals="0" contextRef="D2010Q3" unitRef="USD">51331</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2010Q3" unitRef="USD">9716091</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2010Q3" unitRef="USD">1534417</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2010Q3" unitRef="USD">-11240177</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2010Q3" unitRef="USD">-11589711</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2010Q3" unitRef="USDPerShare">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2010Q4" unitRef="USDPerShare">-1.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues decimals="0" contextRef="D2010Q4" unitRef="USD">143032</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2010Q4" unitRef="USD">11904935</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2010Q4" unitRef="USD">1367491</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="D2010Q4" unitRef="USD">-13168413</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2010Q4" unitRef="USD">-13271735</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:CommonStockSharesAuthorized decimals="INF" contextRef="I2011_CommonStockMember" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare decimals="4" contextRef="I2011_CommonStockMember" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized decimals="INF" contextRef="I2011_CommonClassCMember" unitRef="Shares">4687684</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare decimals="4" contextRef="I2011_CommonClassCMember" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <bpax:CommonStockNumberOfVotesPerShare decimals="INF" contextRef="I2011_CommonClassCMember" unitRef="Item">1</bpax:CommonStockNumberOfVotesPerShare>
  <bpax:CommonStockConversionRatio decimals="2" contextRef="D2011_CommonClassCMember" unitRef="Pure">1.00</bpax:CommonStockConversionRatio>
  <bpax:CommonStockConversionPrice decimals="2" contextRef="I2011_CommonClassCMember" unitRef="USDPerShare">15.00</bpax:CommonStockConversionPrice>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="-5" contextRef="D2011Q3_M0802_CommonStockMember" unitRef="Shares">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice decimals="2" contextRef="I2011Q3_M0802_CommonStockMember" unitRef="USDPerShare">18.00</us-gaap:SharePrice>
  <bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering decimals="-5" contextRef="D2011Q3_M0802_CommonStockMember" unitRef="USD">45000000</bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2011Q1_M0308_CommonStockMember" unitRef="Shares">2033247</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors decimals="INF" contextRef="I2011Q1_M0308_CommonStockMember" unitRef="Shares">711636</bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors>
  <bpax:PurchasePricePerShareToInstitutionalInvestors decimals="4" contextRef="I2011Q1_M0308_CommonStockMember" unitRef="USDPerShare">12.3678</bpax:PurchasePricePerShareToInstitutionalInvestors>
  <bpax:GrossProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2011Q1_M0308_CommonStockMember" unitRef="USD">25100000</bpax:GrossProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2011Q1_M0308_CommonStockMember" unitRef="USD">23900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <bpax:ClassOfWarrantOrRightExpirationPeriod contextRef="D2011Q1_M0308_CommonStockMember">P3Y</bpax:ClassOfWarrantOrRightExpirationPeriod>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2011Due8March2014Member" unitRef="USDPerShare">13.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock decimals="INF" contextRef="I2011Q1_M0308_CommonStockMember" unitRef="Shares">40665</bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2011Due9June2014Member" unitRef="USDPerShare">15.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2010Q1_M0308_CommonStockMember" unitRef="Shares">1734104</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors decimals="INF" contextRef="I2010Q1_M0308_CommonStockMember" unitRef="Shares">867052</bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors>
  <bpax:PurchasePricePerShareToInstitutionalInvestors decimals="2" contextRef="I2010Q1_M0308_CommonStockMember" unitRef="USDPerShare">10.38</bpax:PurchasePricePerShareToInstitutionalInvestors>
  <bpax:NumberOfInstitutionalInvestorsToWhomRegisteredDirectOfferingMade decimals="INF" contextRef="I2010Q1_M0308_CommonStockMember" unitRef="Item">2</bpax:NumberOfInstitutionalInvestorsToWhomRegisteredDirectOfferingMade>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2010Q1_M0308_CommonStockMember" unitRef="USD">17500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2010Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2010Due8September2015Member" unitRef="USDPerShare">12.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock decimals="INF" contextRef="I2010Q1_M0308_CommonStockMember" unitRef="Shares">34682</bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2010Q1_M0308_CommonStockMember_ClassOfWarrantIssuedOn8March2010Due9June2014Member" unitRef="USDPerShare">12.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:StockIssuedDuringPeriodCommonSharesAndWarrants decimals="INF" contextRef="D2010Q2_M0623_CommonStockMember" unitRef="Shares">1189061</bpax:StockIssuedDuringPeriodCommonSharesAndWarrants>
  <bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors decimals="INF" contextRef="I2010Q2_M0623_CommonStockMember" unitRef="Shares">594530</bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors>
  <bpax:PurchasePricePerShareToInstitutionalInvestors decimals="3" contextRef="I2010Q2_M0623_CommonStockMember" unitRef="USDPerShare">12.615</bpax:PurchasePricePerShareToInstitutionalInvestors>
  <bpax:GrossProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2010Q2_M0623_CommonStockMember" unitRef="USD">15000000</bpax:GrossProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2010Q2_M0623_CommonStockMember" unitRef="USD">14100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2010Q2_M0623_CommonStockMember_ClassOfWarrantIssuedOn23June2010Due23June2015Member" unitRef="USDPerShare">14.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock decimals="INF" contextRef="I2010Q2_M0623_CommonStockMember" unitRef="Shares">35671</bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock>
  <bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors decimals="INF" contextRef="I2009_CommonStockMember" unitRef="Shares">440000</bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors>
  <bpax:PurchasePricePerShareToInstitutionalInvestors decimals="2" contextRef="I2010_CommonStockMember" unitRef="USDPerShare">10.20</bpax:PurchasePricePerShareToInstitutionalInvestors>
  <bpax:GrossProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2010_CommonStockMember" unitRef="USD">18000000</bpax:GrossProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="-5" contextRef="D2010_CommonStockMember" unitRef="USD">16900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2010_CommonStockMember_ClassOfWarrantIssuedOn30December2010Due30December2015Member" unitRef="USDPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock decimals="INF" contextRef="I2010_CommonStockMember" unitRef="Shares">52941</bpax:PlacementAgentWarrantsIssuedDuringPeriodCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2010_CommonStockMember_ClassOfWarrantIssuedOn30December2010Due9June2015Member" unitRef="USDPerShare">12.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:BusinessAcquisitionOptionForEquityInterestsIssuedOrIssuableForEachShareOfAcquiree decimals="4" contextRef="I2009Q4_M1031_CommonStockMember_CellGenesysIncMember" unitRef="Pure">0.0305</bpax:BusinessAcquisitionOptionForEquityInterestsIssuedOrIssuableForEachShareOfAcquiree>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued decimals="-5" contextRef="D2009Q4_M10_CommonStockMember_CellGenesysIncMember" unitRef="Shares">3400000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <bpax:BusinessAcquisitionAssumedOptionsConvertedIntoOptionsToPurchaseShares decimals="INF" contextRef="D2009Q4_M10_CommonStockMember_CellGenesysIncMember" unitRef="Shares">39071</bpax:BusinessAcquisitionAssumedOptionsConvertedIntoOptionsToPurchaseShares>
  <bpax:BusinessAcquisitionWeightedAverageExercisePriceOfOption decimals="2" contextRef="D2009Q4_M10_CommonStockMember_CellGenesysIncMember" unitRef="USDPerShare">118.38</bpax:BusinessAcquisitionWeightedAverageExercisePriceOfOption>
  <bpax:BusinessAcquisitionAssumedWarrantsConvertedIntoWarrantsToPurchaseShares decimals="INF" contextRef="D2009Q4_M10_CommonStockMember_CellGenesysIncMember" unitRef="Shares">65874</bpax:BusinessAcquisitionAssumedWarrantsConvertedIntoWarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2009Q4_M1031_CommonStockMember_CellGenesysIncMember" unitRef="USDPerShare">235.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn15December2008Due14June2014Member" unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn15December2008Due14June2014Member" unitRef="USDPerShare">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn21July2009Due20July2012Member" unitRef="USDPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn21July2009Due20July2012Member" unitRef="Shares">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn13August2009Due12August2014Member" unitRef="Shares">400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn13August2009Due12August2014Member" unitRef="USDPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn13August2009Due9June2014Member" unitRef="Shares">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn13August2009Due9June2014Member" unitRef="USDPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn14October2009Due1April2012Member" unitRef="Shares">65874</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn14October2009Due1April2012Member" unitRef="USDPerShare">235.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn8March2010Due8September2015Member" unitRef="Shares">867052</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn8March2010Due8September2015Member" unitRef="USDPerShare">12.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn8March2010Due9June2014Member" unitRef="Shares">34682</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn8March2010Due9June2014Member" unitRef="USDPerShare">12.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn23June2010Due23June2015Member" unitRef="Shares">594530</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn23June2010Due9June2015Member" unitRef="Shares">35671</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn22November2010Due21November2013Member" unitRef="Shares">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn30December2010Due30December2015Member" unitRef="Shares">882353</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn30December2010Due9June2015Member" unitRef="Shares">52941</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn8March2011Due8March2014Member" unitRef="Shares">670971</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights decimals="INF" contextRef="I2011_ClassOfWarrantIssuedOn8March2011Due9June2014Member" unitRef="Shares">40665</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn23June2010Due23June2015Member" unitRef="USDPerShare">14.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn23June2010Due9June2015Member" unitRef="USDPerShare">15.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn22November2010Due21November2013Member" unitRef="USDPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn30December2010Due30December2015Member" unitRef="USDPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn30December2010Due9June2015Member" unitRef="USDPerShare">12.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn8March2011Due8March2014Member" unitRef="USDPerShare">13.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2011_ClassOfWarrantIssuedOn8March2011Due9June2014Member" unitRef="USDPerShare">15.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors decimals="INF" contextRef="I2011_CommonStockMember" unitRef="Shares">711636</bpax:StockIssuedDuringPeriodCommonStockToInstitutionalInvestors>
  <bpax:StockIssuedDuringPeriodSharesWarrantsExercised decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">1458</bpax:StockIssuedDuringPeriodSharesWarrantsExercised>
  <bpax:WarrantsToPurchaseSharesOfCommonStockAsCompensationForInvestorRelation decimals="INF" contextRef="D2010_CommonStockMember" unitRef="Shares">30000</bpax:WarrantsToPurchaseSharesOfCommonStockAsCompensationForInvestorRelation>
  <bpax:BusinessAcquisitionAssumedWarrantsConvertedIntoWarrantsToPurchaseShares decimals="INF" contextRef="D2009_CommonStockMember_CellGenesysIncMember" unitRef="Shares">65874</bpax:BusinessAcquisitionAssumedWarrantsConvertedIntoWarrantsToPurchaseShares>
  <bpax:WarrantsToPurchaseSharesOfCommonStockAsCompensationForInvestorRelation decimals="INF" contextRef="D2009_CommonStockMember" unitRef="Shares">30000</bpax:WarrantsToPurchaseSharesOfCommonStockAsCompensationForInvestorRelation>
  <bpax:WarrantsToPurchaseSharesOfCommonStockAsCompensationForInvestorRelation decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">0</bpax:WarrantsToPurchaseSharesOfCommonStockAsCompensationForInvestorRelation>
  <bpax:PeriodOverWhichWarrantsBecomeExercisableFromDateOfGrant contextRef="D2011_CommonStockMember">P12M</bpax:PeriodOverWhichWarrantsBecomeExercisableFromDateOfGrant>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">204980</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="D2011">&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 84.22%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 339px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="58"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="111"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 38pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Issue Date &lt;!-- COMMAND=ADD_SCROPPEDRULE,38pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Number of&lt;br /&gt;
Underlying&lt;br /&gt;
Shares&lt;br /&gt;
Of Common&lt;br /&gt;
Stock &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Per Share&lt;br /&gt;
Exercise Price &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Expiration Date &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;December&amp;#160;15, 2008&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;24.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;14, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;July&amp;#160;21, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;July&amp;#160;20, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;August&amp;#160;13, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;400,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;August&amp;#160;12, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;August&amp;#160;13, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;40,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;October&amp;#160;14, 2009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;65,874&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;235.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;April&amp;#160;1, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;867,052&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.48&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;September&amp;#160;8, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;34,682&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;June&amp;#160;23, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;594,530&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14.70&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;23, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;June&amp;#160;23, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;35,671&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.78&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;November&amp;#160;22, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;November&amp;#160;21, 2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;December&amp;#160;30, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;882,353&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;December&amp;#160;30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;December&amp;#160;30, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;52,941&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12.75&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;670,971&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13.50&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;March&amp;#160;8, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;40,665&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15.48&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;June&amp;#160;9, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:PreferredStockSharesAuthorized decimals="INF" contextRef="I2011_UndesignatedPreferredStockMember" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare decimals="4" contextRef="I2011_UndesignatedPreferredStockMember" unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2010" unitRef="USD">154111063</us-gaap:CommonStockValueOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised decimals="INF" contextRef="D2010_CommonStockMember" unitRef="Shares">222</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">3194</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:Revenues decimals="0" contextRef="D2010Q2" unitRef="USD">0</us-gaap:Revenues>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2010Q2" unitRef="USD">0</us-gaap:LicenseCosts>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2010Q3" unitRef="USD">0</us-gaap:LicenseCosts>
  <us-gaap:LicenseCosts decimals="0" contextRef="D2010Q4" unitRef="USD">0</us-gaap:LicenseCosts>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage decimals="INF" contextRef="I2009Q4_M1014_ConvertibleNotesPayableMember_CellGenesysIncMember" unitRef="Pure">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <bpax:NumberOfBoardMembersDesignatedByTheEntity decimals="INF" contextRef="D2011" unitRef="Item">1</bpax:NumberOfBoardMembersDesignatedByTheEntity>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2009_CommonClassCMember" unitRef="Shares">65214</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2008_CommonClassCMember" unitRef="Shares">65214</us-gaap:CommonStockSharesIssued>
  <bpax:StockShareWarrantsExpiredUnexercised decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">151868</bpax:StockShareWarrantsExpiredUnexercised>
  <bpax:StockShareWarrantsExpiredUnexercised decimals="INF" contextRef="D2010_CommonStockMember" unitRef="Shares">127291</bpax:StockShareWarrantsExpiredUnexercised>
  <bpax:StockShareWarrantsExpiredUnexercised decimals="INF" contextRef="D2009_CommonStockMember" unitRef="Shares">89166</bpax:StockShareWarrantsExpiredUnexercised>
  <us-gaap:ClassOfWarrantOrRightOutstanding decimals="0" contextRef="I2011_CommonStockMember" unitRef="Shares">3794741</us-gaap:ClassOfWarrantOrRightOutstanding>
  <bpax:PeriodOverWhichWarrantsBecomeExercisableFromDateOfGrant contextRef="D2010_CommonStockMember">P12M</bpax:PeriodOverWhichWarrantsBecomeExercisableFromDateOfGrant>
  <bpax:PeriodOverWhichWarrantsBecomeExercisableFromDateOfGrant contextRef="D2009_CommonStockMember">P12M</bpax:PeriodOverWhichWarrantsBecomeExercisableFromDateOfGrant>
  <bpax:ClassOfWarrantOrRightsExpense decimals="0" contextRef="D2010_CommonStockMember" unitRef="USD">65529</bpax:ClassOfWarrantOrRightsExpense>
  <bpax:ClassOfWarrantOrRightsExpense decimals="0" contextRef="D2009_CommonStockMember" unitRef="USD">64103</bpax:ClassOfWarrantOrRightsExpense>
  <bpax:ClassOfWarrantOrRightsExpense decimals="0" contextRef="D2011_CommonStockMember" unitRef="USD">204980</bpax:ClassOfWarrantOrRightsExpense>
  <bpax:ReverseStockSplitConversionRatio decimals="3" contextRef="I2012Q2_M0601_CommonStockMember" unitRef="Pure">0.167</bpax:ReverseStockSplitConversionRatio>
  <bpax:ReverseStockSplitConversionRatio decimals="3" contextRef="I2012Q2_M0601_CommonClassCMember" unitRef="Pure">0.167</bpax:ReverseStockSplitConversionRatio>
  <us-gaap:ConvertibleLongTermNotesPayable xsi:nil="true" contextRef="I2012Q3" unitRef="USD" />
  <us-gaap:RetainedEarningsAccumulatedDeficit decimals="0" contextRef="I2012Q3" unitRef="USD">-240969556</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity decimals="0" contextRef="I2012Q3" unitRef="USD">32289680</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity decimals="0" contextRef="I2012Q3" unitRef="USD">43211746</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2012Q3_CommonStockMember" unitRef="USD">273259171</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2012Q3_CommonClassCMember" unitRef="USD">65</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2012Q3_CommonClassCMember" unitRef="Shares">65211</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2012Q3_CommonStockMember" unitRef="Shares">24422240</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding decimals="INF" contextRef="I2012Q3_CommonClassCMember" unitRef="Shares">65211</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding decimals="INF" contextRef="I2012Q3_CommonStockMember" unitRef="Shares">24422240</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RoyaltyRevenue decimals="0" contextRef="D2011Q3YTD" unitRef="USD">220787</us-gaap:RoyaltyRevenue>
  <us-gaap:Revenues decimals="0" contextRef="D2011Q3YTD" unitRef="USD">320787</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="D2012Q3YTD" unitRef="USD">333163</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2011Q3YTD" unitRef="USD">37480873</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2011Q3YTD" unitRef="USD">5257853</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2011Q3YTD" unitRef="USD">118132</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-367274</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:CostsAndExpenses decimals="0" contextRef="D2011Q3YTD" unitRef="USD">42856858</us-gaap:CostsAndExpenses>
  <us-gaap:InterestExpense decimals="0" contextRef="D2011Q3YTD" unitRef="USD">516000</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncome decimals="0" contextRef="D2011Q3YTD" unitRef="USD">15000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-44959599</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2011Q3YTD" unitRef="USDPerShare">-2.86</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="0" contextRef="D2011Q3YTD" unitRef="Shares">15744738</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="0" contextRef="D2011Q3YTD" unitRef="Shares">15744738</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensation decimals="0" contextRef="D2011Q3YTD" unitRef="USD">886564</us-gaap:ShareBasedCompensation>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims decimals="0" contextRef="D2011Q3YTD" unitRef="USD">180759</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-1539903</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="D2011Q3YTD" unitRef="USD">2993059</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-36944908</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals="0" contextRef="D2011Q3YTD" unitRef="USD">645603</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-645603</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-536697</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised decimals="0" contextRef="D2011Q3YTD" unitRef="USD">32442</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="0" contextRef="D2011Q3YTD" unitRef="USD">23876370</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2011Q3YTD" unitRef="USD">69035459</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:InterestPaid decimals="0" contextRef="D2011Q3YTD" unitRef="USD">344000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid decimals="0" contextRef="D2012Q3YTD" unitRef="USD">184094</us-gaap:InterestPaid>
  <us-gaap:ProceedsFromWarrantExercises decimals="0" contextRef="D2011Q3YTD" unitRef="USD">24063</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2012Q3" unitRef="USD">38049095</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2011Q3" unitRef="USD">69600199</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2012Q3YTD" unitRef="USD">3479208</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NatureOfOperations contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;1. DESCRIPTION OF BUSINESS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The corporate strategy of BioSante Pharmaceuticals,&amp;#160;Inc. (the Company) is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's products, either approved or in clinical development, include: (1)&amp;#160;LibiGel, once daily transdermal testosterone gel in Phase&amp;#160;III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2)&amp;#160;a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA,&amp;#160;Inc. (Teva); (3)&amp;#160;GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and which are currently in 17 Phase&amp;#160;I and Phase&amp;#160;II clinical trials for the treatment of various cancers; (4)&amp;#160;The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase&amp;#160;II development; and (5)&amp;#160;Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda Pharmaceuticals&amp;#160;Inc. (Meda), the Company's licensee. &lt;/font&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
  <us-gaap:BasisOfAccounting contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;2. BASIS OF PRESENTATION &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In the opinion of management, the accompanying unaudited condensed financial statements contain all necessary adjustments, which are of a normal recurring nature, to present fairly the financial position of the Company as of September&amp;#160;30, 2012, the results of operations for the nine months ended September&amp;#160;30, 2012 and 2011, and the cash flows for the nine months ended September&amp;#160;30, 2012 and 2011, in conformity with accounting principles generally accepted in the United States of America (GAAP). Operating results for the nine month period ended September&amp;#160;30, 2012 are not necessarily indicative of the results that may be expected for the full year ending December&amp;#160;31, 2012. The Company does not have items of other comprehensive income for the nine month period ended September&amp;#160;30, 2012 or 2011; and therefore, has not presented comprehensive income. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;These unaudited interim condensed financial statements should be read in conjunction with the Company's audited financial statements for the year ended December&amp;#160;31, 2011, 2010 and 2009 and related notes contained elsewhere in this joint proxy statement/prospectus. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On June&amp;#160;1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class&amp;#160;C special stock. These unaudited interim condensed financial statements give retroactive effect to the reverse stock split. &lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccounting>
  <bpax:LiquidityAndCapitalResourcesTextBlock contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;3. LIQUIDITY AND CAPITAL RESOURCES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Substantially all of the Company's revenue to date has been derived from upfront, milestone and royalty payments earned on licensing transactions and from subcontracts. The Company's business operations to date have consisted mostly of licensing and research and development activities. The Company itself has not introduced commercially any products. To date, the Company has used primarily equity financings, and to a lesser extent, licensing income, interest income and the cash received from its 2009 merger with Cell Genesys,&amp;#160;Inc. (Cell Genesys), to fund its ongoing business operations and short-term liquidity needs. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of September&amp;#160;30, 2012, the Company had $38,049,095 of cash and cash equivalents. As of September&amp;#160;30, 2012, the Company had outstanding $8,277,850 in aggregate principal amount of its 3.125% convertible senior notes due May&amp;#160;1, 2013. In August 2012, the Company completed an offering of an aggregate of 2,359,932 shares of the Company's common stock and warrants to purchase an aggregate of 1,179,966 shares of the Company's common stock, resulting in net proceeds of $3,268,798, after deducting placement agent fees and other offering expenses. See Note&amp;#160;7, "Stockholders' Equity," for additional discussion regarding the August 2012 registered direct offering. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Absent the receipt of any additional licensing income or financing, the Company expects its cash and cash equivalents balance to decrease as the Company continues to use cash to fund its operations. Assuming the Company's pending merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&amp;#160;Inc. (ANI) is completed during the first quarter of 2013 (see Note&amp;#160;10, "Subsequent Events"), the Company expects its cash and cash equivalents as of September&amp;#160;30, 2012 to meet the Company's liquidity requirements through at least the Company's anticipated closing of the merger, including the requirement under our merger agreement to have at least $17&amp;#160;million of net cash (as defined in the merger agreement) available upon the closing of the merger. If the Company's pending merger with ANI is not completed, the Company will need to reevaluate its strategic alternatives, which may include a sale of the company, liquidation of the company or other strategic transaction. The Company's liquidity position will be dependent upon the strategic alternative selected; however, assuming the Company does not enter into another strategic transaction, and assuming the Company decides not to commence the two new efficacy trials for LibiGel, the Company expects its cash and cash equivalents as of September&amp;#160;30, 2012 will be sufficient to meet the Company's liquidity requirements for at least the next 3-5&amp;#160;years. Additional financing would be required should the Company decide to commence the two new efficacy trials for LibiGel. These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company does not have any existing credit facilities under which the Company could borrow funds. In the event that the Company would require additional working capital to fund future operations, the Company could seek to acquire such funds through additional equity or debt financing arrangements. If the Company raises additional funds by issuing equity securities, the Company's stockholders may experience dilution. Debt financing, if available, may involve covenants restricting the Company's operations or the Company's ability to incur additional debt. There is no assurance that any financing transaction will be available on terms acceptable to the Company, or at all. As an alternative to raising additional financing, the Company may choose to attempt to license one or more of its products or technologies to a third party who may finance a portion or all of the continued development and, if approved, commercialization of that licensed product, sell certain assets or rights under the Company's existing license agreements. In addition, from time to time, the Company may purchase, exchange or restructure its outstanding convertible senior notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer. Such purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the Company's available cash and cash equivalents, the Company's liquidity requirements, contractual restrictions and other factors. Such purchases, exchanges or restructurings could dilute the percentage ownership of the Company's stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of the Company's existing stockholders and/or decrease the Company's cash balance. A significant decrease in the Company's cash balance, together with an inability to raise additional financing when needed, may impair the Company's ability to complete its proposed merger with ANI, execute other strategic alternatives or leave the Company without sufficient cash remaining for operations. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company can provide no assurance that additional financing, if needed, will be available on terms favorable to the Company, or at all. This is particularly true if investors are not confident in the Company's business and future prospects, the future value of the Company and/or economic and market conditions deteriorate. In addition, the Company's ability to raise additional financing is limited by the terms of its agreement and plan of merger with ANI. See Note&amp;#160;10, "Subsequent Events." If adequate funds are not available or are not available on acceptable terms when the Company needs them, the Company may need to reduce its operating costs or the Company may be forced to complete other strategic alternatives, such as winding down its operations and liquidating the Company. In such case, the Company's stockholders could lose some or all of their investment. &lt;/font&gt;&lt;/p&gt;</bpax:LiquidityAndCapitalResourcesTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;4. BASIC AND DILUTED NET LOSS PER SHARE &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The basic and diluted net loss per share is computed based on the weighted average number of shares of common stock and class&amp;#160;C special stock outstanding, all being considered as equivalent of one another. Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding for the reporting period. Diluted net loss per share is intended to reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Because the Company has incurred net losses from operations in each of the periods presented, the Company's outstanding options, warrants and convertible debt are antidilutive; accordingly, such securities are excluded from the computation of diluted net loss per share and there is no difference between basic and diluted net loss per share amounts. &lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;5. CONVERTIBLE SENIOR NOTES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has outstanding 3.125% convertible senior notes due May&amp;#160;1, 2013 (the 2013 Notes). The aggregate principal amount of the 2013 Notes outstanding at September&amp;#160;30, 2012 was $8,277,850. In February 2012, the Company issued 1,868,055 shares of its common stock to one of the holders of the 2013 Notes in exchange for the cancellation of $9,000,000 in aggregate principal amount of such notes and the related accrued and unpaid interest of $79,024. In July 2012, the Company issued an aggregate of 1,784,070 shares of its common stock to two of the holders of the 2013 Notes in exchange for the cancellation of $3,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $20,686. Non-cash fair value adjustments of $(2,545,530) and $(611,621) were recorded during the first and third quarters of 2012 as a result of the cancellation of such notes. The fair value adjustment recorded upon the cancellation of the 2013 Notes is primarily attributable to the time value effect of settling these obligations at a date prior to the stated maturity of the 2013 Notes. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The remaining $8,277,850 aggregate principal amount of the 2013 Notes are exchangeable at the option of the holder or upon certain specified events into an aggregate of approximately 370,871 shares of the Company's common stock at a conversion price of $22.32 per share. The 2013 Notes are general, unsecured obligations of the Company and are described in Note&amp;#160;7 to the Company's financial statements for the year ended December&amp;#160;31, 2011. As of September&amp;#160;30, 2012, the 2013 Notes were not eligible for redemption. The indenture governing the 2013 Notes, as supplemented by the supplemental indenture, does not contain any financial covenants and does not restrict the Company from paying dividends, incurring additional debt or issuing or repurchasing the Company's other securities. In addition, the indenture, as supplemented by the supplemental indenture, does not protect the holders of the 2013 Notes in the event of a highly leveraged transaction or a fundamental change of the Company except in certain circumstances specified in the indenture. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As described in Note&amp;#160;3, "Liquidity and Capital Resources," from time to time, the Company may purchase, exchange or restructure its outstanding 2013 Notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has elected to record the 2013 Notes at fair value in order to simplify the accounting for the convertible debt, inclusive of the redemption, repurchase and conversion adjustment features which otherwise would require specialized valuation, bifurcation and recognition. Accordingly, the Company has adjusted the carrying value of the 2013 Notes to their fair value as of September&amp;#160;30, 2012, with changes in the fair value of the 2013 Notes occurring since December&amp;#160;31, 2011, reflected in fair value adjustment in the unaudited condensed statements of operations. As described in Note&amp;#160;9, "Fair Value Measurements," the fair value of the 2013 Notes is based on Level&amp;#160;2 inputs. The recorded fair value of the 2013 Notes of an aggregate of $7,593,216 as of September&amp;#160;30, 2012 differs from their total stated aggregate principal amount of $8,277,850 as of such date by $684,634. During the nine months ended September&amp;#160;30, 2012, the Company recorded a fair value adjustment of $(4,037,797) related to the 2013 Notes that were converted to common stock during 2012 or that remained outstanding as of September&amp;#160;30, 2012, that for the nine months ended September&amp;#160;30, 2012 increased the recorded liability and corresponding expense. For the nine months ended September&amp;#160;30, 2011, the Company recorded a fair value adjustment of $(1,929,000) that increased the recorded liability and corresponding expense, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;For the nine months ended September&amp;#160;30, 2012 and 2011, approximately $(41,000) and $230,000, respectively, of the fair value adjustment was attributable to the change in instrument specific credit risk. The change in the aggregate fair value of the 2013 Notes due to instrument specific credit risk for the nine months ended September&amp;#160;30, 2012 was estimated by calculating the difference between the September&amp;#160;30, 2012 fair value of the 2013 Notes as recorded and what the fair value of the 2013 Notes would have been on September&amp;#160;30, 2012 if the December&amp;#160;31, 2011 discount rate continued to be used in the calculation. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The instrument specific credit risk for both periods has increased the fair value of the 2013 Notes as market borrowing rates have decreased for similarly rated companies and are estimated to have decreased for the Company as well, indicating a lower credit spread assuming no significant changes in the risk-free borrowing rate. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company establishes the value of the 2013 Notes based upon contractual terms of the 2013 Notes, as well as certain key assumptions. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The assumptions as of September&amp;#160;30, 2012 were: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="26"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;0.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;90.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;19.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The discount rate is based on observed yields as of the measurement date for debt securities of entities having a Ca and Caa3 rating for long-term corporate obligations as assigned by Moody's Investors Service. Volatility is based on the historical fluctuations in the Company's stock price for a period of time equal to the remaining time until the debt maturity. The risk-free rate is based on observed yields as of the measurement date of six month and one-year U.S. Treasury Bonds. &lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;6. STOCK-BASED COMPENSATION &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company typically grants options to purchase shares of the Company's common stock to existing employees and non-employee directors on an annual basis during the first quarter of each year and to new employees and non-employee directors throughout the year on or around the date their employment or service with the Company commences. All options are granted under the BioSante Pharmaceuticals,&amp;#160;Inc. Amended and Restated 2008 Stock Incentive Plan (the 2008 Plan). As of September&amp;#160;30, 2012, approximately 981,272 shares of the Company's common stock remain available for issuance under the 2008 Plan. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During the nine months ended September&amp;#160;30, 2012, the Company granted options under the 2008 Plan to purchase an aggregate of 358,582 shares of the Company's common stock to certain employees of the Company and the Company's non-employee directors with a weighted average exercise price of $4.08 per share. Options to purchase an aggregate of 105,781 shares of the Company's common stock expired and were cancelled during the nine months ended September&amp;#160;30, 2012. Options are granted at an exercise price equal to the closing price of the Company's common stock on the date of the grant. No options were exercised during the nine months ended September&amp;#160;30, 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;No warrants were granted during the nine months ended September&amp;#160;30, 2012, other than the warrants issued in conjunction with the Company's August 2012 offering described in Note&amp;#160;7, "Stockholders' Equity". &lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;7. STOCKHOLDERS' EQUITY &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During the nine months ended September&amp;#160;30, 2012, the Company issued an aggregate of 3,652,125 shares of its common stock to holders of the 2013 Notes in exchange for the cancellation of $12,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $99,710. See Note&amp;#160;5, "Convertible Senior Notes" for information regarding the 2013 Notes. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In August 2012, the Company completed an offering of 2,359,932 shares of its common stock and warrants to purchase an aggregate of 1,179,966 shares of its common stock at a purchase price of $1.4725 per share to one institutional investor for gross proceeds of $3,475,000. The offering resulted in net proceeds to the Company of $3,268,798, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately and continue for a period of 5&amp;#160;years, at an exercise price of $1.50 per share. The number of shares issuable upon exercise of the warrants and the exercise price of the warrants are adjustable in the event of stock splits, combinations and reclassifications, but not in the event of the issuance of additional securities. On September&amp;#160;20, 2012, warrants from the August 2012 offering to purchase an aggregate of 140,712 shares of common stock were exercised resulting in proceeds of $211,068 to the Company. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On May&amp;#160;30, 2012, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to effect a reverse split of the Company's outstanding shares of common stock and class&amp;#160;C special stock in the discretion of the Company's Board of Directors at an exchange ratio of not less than one-for-two and not more than one-for-ten. On June&amp;#160;1, 2012, the Board of Directors of the Company effected a one-for-six reverse split of the Company's outstanding shares of common stock and class&amp;#160;C special stock. No fractional shares were issued as a result of the reverse stock split, and stockholders who otherwise would have been entitled to a fractional share received, in lieu thereof, a cash payment based on the closing sale price of BioSante's common stock on June&amp;#160;1, 2012. The total cash payment for fractional shares was $658. The reverse stock split did not change the number of authorized shares of the Company's common stock or class&amp;#160;C special stock or the par value of the Company's common stock or class&amp;#160;C special stock, but because the number of authorized shares of the Company's common stock and class&amp;#160;C special stock was not affected, the effect of the reverse stock split was to increase the number of authorized but unissued shares of the Company's common stock and class&amp;#160;C special stock. The primary purpose of the reverse stock split was to increase the Company's ability to maintain the listing of its common stock on The NASDAQ Global Market. &lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="D2012Q3YTD">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;9. FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company accounts for its convertible debt and U.S. Treasury money market fund at fair value. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="LIST-STYLE-TYPE: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1:&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&amp;#160;1 inputs. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2:&amp;#160;&amp;#160;&amp;#160;&amp;#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3:&amp;#160;&amp;#160;&amp;#160;&amp;#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&amp;#160;3 inputs. &lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Financial assets and liabilities recorded at fair value on a recurring basis as of September&amp;#160;30, 2012 are classified in the table below in one of the three categories described above: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 89.33%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 189px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"110%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 41pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,41pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;br /&gt;
2012 Balance &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Quoted Prices in&lt;br /&gt;
Active Markets&lt;br /&gt;
for Identical&lt;br /&gt;
Assets (Level&amp;#160;1) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs (Level&amp;#160;2) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs (Level&amp;#160;3) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company made an election to record the values of the 2013 Notes at fair value with gains and losses related to fluctuations in the value of these financial liabilities recorded in earnings immediately. The fair values of the 2013 Notes are estimated based on the risk-free borrowing rate, the volatility of the Company's stock, and the current borrowing rates for similar companies. See Note&amp;#160;6, "Convertible Senior Notes" for more information and disclosures regarding key assumptions used in this fair value determination. &lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:LiabilitiesCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">10922066</us-gaap:LiabilitiesCurrent>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-1929000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:CostsAndExpenses decimals="0" contextRef="D2012Q3YTD" unitRef="USD">19869517</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2011Q3YTD" unitRef="USD">31444948</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <bpax:NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation decimals="INF" contextRef="D2012Q3YTD" unitRef="Vaccine">4</bpax:NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities decimals="INF" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Shares">3652125</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage decimals="INF" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="Pure">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering decimals="0" contextRef="D2011Q3YTD" unitRef="USD">45102584</bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering>
  <bpax:ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock contextRef="D2012Q3YTD">
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 86.31%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 35px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="26"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;0.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;90.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;19.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</bpax:ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 decimals="2" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USDPerShare">22.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:LongTermDebtFairValue decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">7593216</us-gaap:LongTermDebtFairValue>
  <us-gaap:DebtInstrumentFaceAmount decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">8277850</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">684634</us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate decimals="4" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Pure">0.0014</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate decimals="3" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Pure">0.900</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <bpax:FairValueAssumptionsDiscountRate decimals="3" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Pure">0.196</bpax:FairValueAssumptionsDiscountRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant decimals="0" contextRef="I2012Q3" unitRef="Shares">981272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross decimals="INF" contextRef="D2012Q3YTD_StockOptionsMember_SB" unitRef="Shares">358582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice decimals="2" contextRef="D2012Q3YTD_StockOptionsMember_SB" unitRef="USDPerShare">4.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod decimals="INF" contextRef="D2012Q3YTD_StockOptionsMember_SB" unitRef="Shares">105781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="D2012Q3YTD">&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 79.73%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 223px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="110%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="75"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 41pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,41pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;br /&gt;
2012 Balance &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Quoted Prices in&lt;br /&gt;
Active Markets&lt;br /&gt;
for Identical&lt;br /&gt;
Assets (Level&amp;#160;1) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs (Level&amp;#160;2) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs (Level&amp;#160;3) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36,957,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,593,216&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2012Q3_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2012Q3_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure decimals="0" contextRef="I2012Q3_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures decimals="0" contextRef="I2012Q3_FairValueInputsLevel2Member_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:LiabilitiesFairValueDisclosure decimals="0" contextRef="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure decimals="0" contextRef="I2012Q3_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments decimals="INF" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Shares">370871</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:InvestmentIncomeInterest decimals="0" contextRef="D2011Q3YTD" unitRef="USD">6472</us-gaap:InvestmentIncomeInterest>
  <us-gaap:StockIssued1 decimals="0" contextRef="D2012Q3YTD" unitRef="USD">13881052</us-gaap:StockIssued1>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid decimals="0" contextRef="D2011Q3YTD" unitRef="USD">59016</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="D2012Q3YTD">&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;8. COMMITMENTS AND CONTINGENCIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Aptar Pharma&amp;#8212;Gel Packaging Machine &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has a commitment with Aptar Pharma to purchase a gel packaging machine for $844,740. As of September&amp;#160;30, 2012, the Company had paid Aptar $804,132. The remaining obligation of $40,608 is due upon the shipment, assembly and calibration of the machine at a location designated by the Company. In light of the Company's pending merger with ANI (see Note&amp;#160;10, "Subsequent Events"), the Company is evaluating the future plans for this gel packaging machine. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Pending Litigation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On February&amp;#160;3, 2012, a purported class action lawsuit was filed in the United States District Court for the Northern District of Illinois under the caption &lt;/font&gt;&lt;font size="2"&gt;&lt;i&gt;Thomas Lauria, on behalf of himself and all others similarly situated v. BioSante Pharmaceuticals,&amp;#160;Inc. and Stephen M. Simes&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt; naming the Company and the Company's President and Chief Executive Officer, Stephen M. Simes, as defendants. The complaint alleges that certain of the Company's disclosures relating to the efficacy of LibiGel and its commercial potential were false and/or misleading and that such false and/or misleading statements had the effect of artificially inflating the price of the Company's securities resulting in violations of Section&amp;#160;10(b) of the Securities Exchange Act of 1934, as amended (Exchange Act), Rule&amp;#160;10b-5 and Section&amp;#160;20(a) of the Exchange Act. Although a substantially similar complaint was filed in the same court on February&amp;#160;21, 2012, such complaint was voluntarily dismissed by the plaintiff in April 2012. The plaintiff seeks to represent a class of persons who purchased the Company's securities between February&amp;#160;10, 2010 and December&amp;#160;15, 2011, and seeks unspecified compensatory damages, equitable and/or injunctive relief, and reasonable costs, expert fees and attorneys' fees on behalf of such purchasers. The Company believes the action is without merit and intends to defend the action vigorously. On October&amp;#160;10, 2012, the District Court entered an order setting the dates on which the plaintiff's consolidated amended complaint is due and establishing a briefing schedule on the defendants' anticipated motion to dismiss. On November&amp;#160;6, 2012, plaintiff filed a consolidated amended complaint; the Company and Mr.&amp;#160;Simes intend to file motions to dismiss the consolidated amended complaint on or before December&amp;#160;21, 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On May&amp;#160;7, 2012, Jerome W. Weinstein, a purported stockholder of the Company filed a shareholder derivative action in the United States District Court for the Northern District of Illinois under the caption &lt;/font&gt;&lt;font size="2"&gt;&lt;i&gt;Weinstein v. BioSante Pharmaceuticals,&amp;#160;Inc. et al.&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;, naming the Company's directors as defendants and the Company as a nominal defendant. A substantially similar complaint was filed in the same court on May&amp;#160;22, 2012 and another substantially similar complaint was filed in the Circuit Court for Cook County, Illinois, County Department, Chancery Division, on June&amp;#160;27, 2012. The suits generally related to the same events that are the subject of the class action litigation described above. The complaints allege breaches of fiduciary duty, abuse of control, gross mismanagement and unjust enrichment as causes of action occurring from at least February 2010 through December 2011. The complaints seek unspecified damages, punitive damages, costs and disbursements and unspecified reform and improvements in the Company's corporate governance and internal control procedures. On September&amp;#160;24, 2012, the District Court consolidated the two cases before it and entered a stipulation and order setting the dates on which the plaintiff's consolidated amended complaint is due and establishing a briefing schedule on defendants' anticipated motions to dismiss. The Company expects a similar scheduling order to be entered in the action pending in Illinois state court. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The lawsuits are in their early stages; and, therefore, the Company is unable to predict the outcome of the lawsuits and the possible loss or range of loss, if any, associated with their resolution or any potential effect the lawsuits may have on the Company's operations. Depending on the outcome or resolution of these lawsuits, they could have a material effect on the Company's operations, including its financial condition, results of operations, or cash flows. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is not involved in any other legal actions, however, from time to time may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business. Such matters are subject to many uncertainties and to outcomes that are not predictable with reasonable assurance and that may not be known for extended periods of time. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="0" contextRef="D2012Q3YTD" unitRef="Shares">20841417</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="0" contextRef="D2012Q3YTD" unitRef="Shares">20841417</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-4037797</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2012Q3YTD" unitRef="USDPerShare">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PropertyPlantAndEquipmentNet decimals="0" contextRef="I2012Q3" unitRef="USD">1184764</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets decimals="0" contextRef="I2012Q3" unitRef="USD">43211746</us-gaap:Assets>
  <us-gaap:SeniorNotesCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">7593216</us-gaap:SeniorNotesCurrent>
  <us-gaap:Liabilities decimals="0" contextRef="I2012Q3" unitRef="USD">10922066</us-gaap:Liabilities>
  <us-gaap:CommonStockValueOutstanding decimals="0" contextRef="I2012Q3" unitRef="USD">273259236</us-gaap:CommonStockValueOutstanding>
  <us-gaap:PaymentsToAcquireInvestments decimals="0" contextRef="D2012Q3YTD" unitRef="USD">7955</us-gaap:PaymentsToAcquireInvestments>
  <bpax:PaymentsToFractionalSharePayout decimals="0" contextRef="D2012Q3YTD" unitRef="USD">658</bpax:PaymentsToFractionalSharePayout>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-19176139</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities decimals="INF" contextRef="D2012Q1_M02_ConvertibleNotesPayableMember" unitRef="Shares">1868055</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <bpax:StockholdersEquityReverseStockSplitConversionRatio decimals="4" contextRef="D2012Q2_M06" unitRef="Pure">0.1667</bpax:StockholdersEquityReverseStockSplitConversionRatio>
  <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities decimals="0" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="USD">-41000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
  <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities decimals="0" contextRef="D2011Q3YTD_ConvertibleNotesPayableMember" unitRef="USD">230000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
  <bpax:StockholdersEquityReverseStockSplitConversionRatio decimals="1" contextRef="D2012Q2_M05_MinimumMember" unitRef="Pure">0.5</bpax:StockholdersEquityReverseStockSplitConversionRatio>
  <bpax:StockholdersEquityReverseStockSplitConversionRatio decimals="1" contextRef="D2012Q2_M05_MaximumMember" unitRef="Pure">0.1</bpax:StockholdersEquityReverseStockSplitConversionRatio>
  <us-gaap:LongTermPurchaseCommitmentAmount decimals="0" contextRef="D2012Q3YTD_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">844740</us-gaap:LongTermPurchaseCommitmentAmount>
  <bpax:PurchaseCommitmentCumulativePaymentsToAcquireMachinery decimals="0" contextRef="I2012Q3_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">804132</bpax:PurchaseCommitmentCumulativePaymentsToAcquireMachinery>
  <us-gaap:PurchaseObligation decimals="0" contextRef="I2012Q3_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">40608</us-gaap:PurchaseObligation>
  <bpax:UnpaidCostsAssociatedWithUnderWrittenPublicOffering decimals="0" contextRef="D2011Q3YTD" unitRef="USD">141447</bpax:UnpaidCostsAssociatedWithUnderWrittenPublicOffering>
  <bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued decimals="INF" contextRef="D2012Q1_M02_ConvertibleNotesPayableMember" unitRef="Holder">1</bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued>
  <bpax:NumberOfPhaseIAndPhaseIIClinicalTrials decimals="INF" contextRef="D2012Q3YTD" unitRef="Item">17</bpax:NumberOfPhaseIAndPhaseIIClinicalTrials>
  <us-gaap:DebtConversionOriginalDebtAmount1 decimals="0" contextRef="D2012Q1_M02_ConvertibleNotesPayableMember" unitRef="USD">9000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtConversionOriginalDebtAmount1 decimals="0" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="USD">12504150</us-gaap:DebtConversionOriginalDebtAmount1>
  <bpax:FairValueOptionChangesInFairValueNonCashAdjustment decimals="0" contextRef="D2012Q3_ConvertibleNotesPayableMember" unitRef="USD">-611621</bpax:FairValueOptionChangesInFairValueNonCashAdjustment>
  <us-gaap:SubsequentEventsTextBlock contextRef="D2012Q3YTD">
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;10. SUBSEQUENT EVENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Agreement and Plan of Merger &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On October&amp;#160;3, 2012, the Company entered into an agreement and plan of merger (the Merger Agreement) with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&amp;#160;Inc. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, ANI will merge with and into the Company, with the Company continuing as the surviving company (the Merger). At the effective time of the Merger, each outstanding share of capital stock of ANI will be converted into the right to receive a number of shares of the Company's common stock, if any, as determined pursuant to the exchange ratios described in the Merger Agreement and the provisions of ANI's certificate of incorporation. All options, warrants or other rights to purchase shares of capital stock of ANI, will be canceled at the effective time of the Merger without any consideration in exchange, except for certain warrants which although not cancelled will not represent the right to acquire any equity or other interest in the combined company after the Merger. No fractional shares of the Company's common stock will be issued in connection with the Merger, and holders of ANI capital stock will be entitled to receive cash in lieu thereof. Following the consummation of the transactions contemplated by the Merger Agreement, the current stockholders of ANI are expected to own approximately 53&amp;#160;percent of the outstanding shares of common stock of the combined company, and current stockholders of the Company are expected to own approximately 47&amp;#160;percent of the outstanding shares of common stock of the combined company. The exchange ratios are subject to potential adjustment as described in the Merger Agreement depending upon the amount of the Company's "net cash", as defined in the Merger Agreement and generally consisting of the Company's cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the Merger, but in no event will the current ANI stockholders own less than 50.1&amp;#160;percent (or the current Company stockholders own more than 49.9&amp;#160;percent) of the outstanding shares of common stock of the combined company. The Merger is intended to qualify as a "reorganization" within the meaning of Section&amp;#160;368(a) of the Internal Revenue Code of 1986, as amended. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Merger Agreement provides that, immediately following the effective time of the Merger, the board of directors of the combined company will consist of five former directors of ANI and two former directors of the Company, and ANI's current executive officers are expected to serve as executive officers of the combined company. In connection with the Merger, the Company will seek to amend its certificate of incorporation to: (i)&amp;#160;effect a reverse split of its common stock at a ratio between the range of one-for-two and one-for-five, as determined by the Company and ANI, which is intended to ensure that the listing requirements of The NASDAQ Global Market or The NASDAQ Capital Market are satisfied; and (ii)&amp;#160;change the name of the Company to "ANI Pharmaceuticals,&amp;#160;Inc." or another name as designated by ANI (together, the Charter Amendments). No fractional shares of the Company's common stock will be issued in connection with the reverse split and holders of the Company's common stock will be entitled to receive cash in lieu thereof. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Consummation of the Merger is subject to a number of conditions, including, but not limited to (i)&amp;#160;the adoption and approval of the Merger Agreement and the transactions contemplated thereby by both the Company's and ANI's stockholders and the approval of the Charter Amendments by the Company's stockholders; (ii)&amp;#160;the effectiveness of a Form&amp;#160;S-4 registration statement to be filed by the Company with the Securities and Exchange Commission to register the shares of the Company's common stock to be issued in connection with the Merger, which will contain a joint proxy statement/prospectus; (iii)&amp;#160;approval for the listing of shares of the Company's common stock to be issued in the Merger on The NASDAQ Global Market or The NASDAQ Capital Market; (iv)&amp;#160;written opinions of counsel that the Merger will qualify as a reorganization within the meaning of Section&amp;#160;368(a) of the Code; and (v)&amp;#160;other customary closing conditions. In addition, the obligation of ANI to effect the Merger is subject to a condition that the Company's net cash, as calculated pursuant to the terms of the Merger Agreement, be no less than $17.0&amp;#160;million immediately prior to the effective time of the Merger. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Each of the Company and ANI have made customary representations, warranties and covenants in the Merger Agreement, including among others, covenants that (i)&amp;#160;each party will conduct its business in the ordinary course consistent with past practice during the interim period between the execution of the Merger Agreement and the consummation of the Merger; (ii)&amp;#160;each party will not engage in certain kinds of transactions or take certain actions during such period; (iii)&amp;#160;ANI will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the board of directors of ANI will recommend that its stockholders adopt and approve the Merger Agreement, subject to certain exceptions; and (iv)&amp;#160;the Company will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the approval of the Charter Amendments and the Company's board of directors will recommend that the Company's stockholders adopt and approve the Merger Agreement and approve the charter amendments, subject to certain exceptions. Each of the Company and ANI also has agreed not to solicit proposals relating to alternative business combination transactions or enter into discussions or an agreement concerning any proposals for alternative business combination transactions, subject to exceptions for the Company in the event of the Company's receipt of a "superior proposal." &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Merger Agreement contains certain termination rights in favor of each of ANI and the Company in certain circumstances. If the Merger Agreement is terminated due to certain triggering events specified in the Merger Agreement, the Company will be required to pay ANI a termination fee of up to $1.0&amp;#160;million or ANI will be required to pay the Company a termination fee of up to $750,000. The Merger Agreement also provides that under specified circumstances, the Company may be required to reimburse ANI up to $500,000 for ANI's expenses in connection with the transaction. Any expenses paid by the Company will be credited against the $1.0&amp;#160;million termination fee if the termination fee subsequently becomes payable by the Company. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Voting Agreements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Concurrently and in connection with the execution of the Merger Agreement, certain of ANI's stockholders, who collectively hold approximately 90&amp;#160;percent of the outstanding shares of ANI capital stock as of the close of business on October&amp;#160;3, 2012, entered into voting agreements with the Company, pursuant to which each stockholder agreed to vote its shares of ANI capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement. In addition, one of the stockholders of ANI, who holds approximately 57&amp;#160;percent of the outstanding shares of ANI capital stock as of the close of business on October&amp;#160;3, 2012, has agreed to vote in favor of the election of the two directors designated by the Company at the first annual meeting of stockholders following the completion of the Merger. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In addition, certain of the Company's stockholders, directors and officers, who collectively hold approximately two percent of the outstanding shares of the Company's capital stock as of the close of business on October&amp;#160;3, 2012, entered into voting agreements with ANI, pursuant to which each stockholder agreed to vote its shares of the Company's capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and the charter amendments, and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Lock-Up Agreements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Concurrently and in connection with the execution of the Merger Agreement, ANI's chief executive officer and chief financial officer and certain stockholders of ANI, who collectively hold approximately 85&amp;#160;percent of the outstanding shares of ANI capital stock as of the close of business on October&amp;#160;3, 2012, entered into lock-up agreements with the Company, pursuant to which each stockholder will be subject to a six-month lock-up on the sale of shares of the Company's common stock received in the Merger. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Contingent Value Rights Agreement &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has the right in its sole discretion to issue contingent value rights (each, a CVR and collectively, the CVRs) to its existing stockholders immediately prior to the completion of the Merger. The Company expects that one CVR will be issued for each share of the Company's common stock outstanding as of the record date to be set at a date prior to the completion of the Merger. However, the CVRs will not be certificated and will not be attached to the shares of the Company's common stock. Each CVR will be a non-transferable (subject to certain limited exceptions) right to potentially receive certain cash payments in the event the Company receives net cash payments during the ten-year period after the distribution of the rights as a result of the sale, transfer, license or similar transaction relating to the Company's LibiGel program, upon the terms and subject to the conditions set forth in a contingent value rights agreement to be entered into between the Company and an as of yet unidentified third party, as rights agent. The aggregate cash payments to be distributed to the holders of the CVRs, if any, will be equal to 66&amp;#160;percent of the net cash payments received by the combined company as a result of the sale, transfer, license or similar transaction relating to the Company's LibiGel program, as determined pursuant to the CVR agreement, and will not exceed $40&amp;#160;million in the aggregate. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Employee Reduction Implications &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As a result of the conclusion of the Company's LibiGel Phase&amp;#160;III cardiovascular events and breast cancer safety study, as announced by the Company in September 2012, and considering the Company's October&amp;#160;4, 2012 announcement of its potential merger with ANI, the Company plans to reduce its workforce during the fourth quarter of 2012. In connection with the announced reduction, the Company will pay approximately $300,000 in aggregate severance costs during the remainder of 2012. The termination of employment of these employees will result in the cessation of any further vesting in certain stock options held by these employees and a reversal of previously recognized non-cash stock-based compensation expense related to such options in a similar amount, thereby offsetting the employee reduction severance costs. &lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Third Amendment To License Agreement with Teva &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In October 2012, the Company entered into an amendment to its development and license agreement with Teva pursuant to which Teva made a $1.0&amp;#160;million payment to the Company upon the signing of the amendment and agreed to make the following milestone-based payments to the Company: (1)&amp;#160;$500,000 if the FDA authorizes marketing of the licensed male testosterone gel as an "AB-rated" equivalent to AndroGel&amp;#174;; (2)&amp;#160;$750,000 upon the earlier to occur of (a)&amp;#160;December&amp;#160;31, 2012 and (b)&amp;#160;five business days after Teva's submission to the FDA of a final report regarding a "washing" clinical study required by the FDA; and (3)&amp;#160;$500,000 upon the earlier to occur of (a)&amp;#160;December&amp;#160;31, 2013 and (b)&amp;#160;five business days after Teva's commencement of commercial manufacture of the licensed product for sale in the United States. In addition, Teva has agreed to pay the Company $4.0&amp;#160;million in the event Teva is the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel&amp;#174; for at least 180&amp;#160;days immediately following the launch date of the licensed product in the United States. The royalty rate to be paid by Teva to the Company under the agreement is five percent of net sales; provided, however, that during the period of time that Teva markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel&amp;#174; in the United States, the royalty rate will be seven and one half percent of net sales. Additionally, pursuant to the terms of the October 2012 amendment, the parties agreed to release each other from certain liabilities. &lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:InterestPayableCurrentAndNoncurrent decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">99710</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:LicensesRevenue decimals="0" contextRef="D2011Q3YTD" unitRef="USD">100000</us-gaap:LicensesRevenue>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_SubsequentEventMember" unitRef="Pure">0.53</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders decimals="2" contextRef="I2012Q4_M1003_MergerAgreementMember_SubsequentEventMember" unitRef="Pure">0.47</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders decimals="3" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="Pure">0.501</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders decimals="3" contextRef="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="Pure">0.499</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany decimals="INF" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_SubsequentEventMember" unitRef="Item">5</bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany>
  <bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany decimals="INF" contextRef="I2012Q4_M1003_MergerAgreementMember_SubsequentEventMember" unitRef="Item">2</bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany>
  <bpax:ReverseStockSplitConversionRatio decimals="1" contextRef="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="Pure">0.5</bpax:ReverseStockSplitConversionRatio>
  <bpax:NetCashRequiredToObligateEntityToEffectMerger decimals="-5" contextRef="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="USD">17000000</bpax:NetCashRequiredToObligateEntityToEffectMerger>
  <bpax:BusinessMergerTerminationFeePayable decimals="-5" contextRef="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">1000000</bpax:BusinessMergerTerminationFeePayable>
  <bpax:BusinessMergerTerminationFeePayable decimals="0" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">750000</bpax:BusinessMergerTerminationFeePayable>
  <bpax:BusinessMergerReimbursementOfExpenses decimals="0" contextRef="D2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">500000</bpax:BusinessMergerReimbursementOfExpenses>
  <bpax:PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Pure">0.90</bpax:PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders>
  <bpax:NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock decimals="INF" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Item">1</bpax:NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock>
  <bpax:PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Pure">0.57</bpax:PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors>
  <bpax:NumberOfDirectorsDesignatedByEntity decimals="INF" contextRef="D2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Item">2</bpax:NumberOfDirectorsDesignatedByEntity>
  <bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Pure">0.02</bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements>
  <bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember" unitRef="Pure">0.85</bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements>
  <bpax:LockingPeriodOnSaleOfSharesPostMerger contextRef="D2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember">P6M</bpax:LockingPeriodOnSaleOfSharesPostMerger>
  <bpax:NumberOfContingentValueRightsIssuedInExchangeForOneShare decimals="INF" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember" unitRef="Shares">1</bpax:NumberOfContingentValueRightsIssuedInExchangeForOneShare>
  <bpax:PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights contextRef="D2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember">P10Y</bpax:PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights>
  <bpax:NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember" unitRef="Pure">0.66</bpax:NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived>
  <bpax:AggregateNetCashPaymentsToBeDistributedToHolders decimals="-6" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">40000000</bpax:AggregateNetCashPaymentsToBeDistributedToHolders>
  <bpax:ReverseStockSplitConversionRatio decimals="1" contextRef="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="Pure">0.2</bpax:ReverseStockSplitConversionRatio>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities decimals="INF" contextRef="D2012Q3_M07_ConvertibleNotesPayableMember" unitRef="Shares">1784070</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:InterestPayableCurrentAndNoncurrent decimals="0" contextRef="I2012Q3_M0731_ConvertibleNotesPayableMember" unitRef="USD">20686</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent decimals="0" contextRef="I2012Q1_M0229_ConvertibleNotesPayableMember" unitRef="USD">79024</us-gaap:InterestPayableCurrentAndNoncurrent>
  <bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued decimals="INF" contextRef="D2012Q3_M07_ConvertibleNotesPayableMember" unitRef="Holder">2</bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued>
  <us-gaap:DebtConversionOriginalDebtAmount1 decimals="0" contextRef="D2012Q3_M07_ConvertibleNotesPayableMember" unitRef="USD">3504150</us-gaap:DebtConversionOriginalDebtAmount1>
  <bpax:FairValueOptionChangesInFairValueNonCashAdjustment decimals="0" contextRef="D2012Q1_ConvertibleNotesPayableMember" unitRef="USD">-2545530</bpax:FairValueOptionChangesInFairValueNonCashAdjustment>
  <bpax:NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing decimals="INF" contextRef="D2012Q3YTD_MinimumMember" unitRef="Item">1</bpax:NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="0" contextRef="D2012Q3_M08_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember" unitRef="Shares">1179966</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="0" contextRef="D2012Q3_M08_CommonStockMember" unitRef="Shares">2359932</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity decimals="0" contextRef="D2012Q3_M08_CommonStockMember" unitRef="USD">3268798</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:SharePrice decimals="4" contextRef="I2012Q3_M0831_CommonStockMember" unitRef="USDPerShare">1.4725</us-gaap:SharePrice>
  <bpax:ProceedsFromIssuanceOfCommonStockGross decimals="0" contextRef="D2012Q3_M08_CommonStockMember" unitRef="USD">3475000</bpax:ProceedsFromIssuanceOfCommonStockGross>
  <bpax:NumberOfInstitutionalInvestorsToWhomOfferingMade decimals="0" contextRef="I2012Q3_M0831_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember" unitRef="Item">1</bpax:NumberOfInstitutionalInvestorsToWhomOfferingMade>
  <bpax:ClassOfWarrantOrRightTermOfWarrants contextRef="D2012Q3_M08_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember">P5Y</bpax:ClassOfWarrantOrRightTermOfWarrants>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights decimals="2" contextRef="I2012Q3_M0831_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember" unitRef="USDPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">534037</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">38583132</us-gaap:AssetsCurrent>
  <us-gaap:LongTermInvestments decimals="0" contextRef="I2012Q3" unitRef="USD">3413762</us-gaap:LongTermInvestments>
  <us-gaap:DepositsAssetsNoncurrent decimals="0" contextRef="I2012Q3" unitRef="USD">30088</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:AccountsPayableCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">2004814</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">463942</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent decimals="0" contextRef="I2012Q3" unitRef="USD">860094</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:RoyaltyRevenue decimals="0" contextRef="D2012Q3YTD" unitRef="USD">333163</us-gaap:RoyaltyRevenue>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2012Q3YTD" unitRef="USD">14454258</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2012Q3YTD" unitRef="USD">5327711</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2012Q3YTD" unitRef="USD">87548</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestExpense decimals="0" contextRef="D2012Q3YTD" unitRef="USD">283348</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest decimals="0" contextRef="D2012Q3YTD" unitRef="USD">5300</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-23730408</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-117794</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ShareBasedCompensation decimals="0" contextRef="D2012Q3YTD" unitRef="USD">852468</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-323225</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-3807074</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-22118650</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals="0" contextRef="D2012Q3YTD" unitRef="USD">528742</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromWarrantExercises decimals="0" contextRef="D2012Q3YTD" unitRef="USD">211068</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="0" contextRef="D2012Q3YTD" unitRef="USD">3268798</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="0" contextRef="D2012Q3_M0920_CommonStockMember" unitRef="Shares">140712</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <bpax:ProceedsFromIssuanceOfCommonStockGross decimals="0" contextRef="D2012Q3_M0920_CommonStockMember" unitRef="USD">211068</bpax:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:SeveranceCosts decimals="0" contextRef="D2012_ANIPharmaceuticalsIncMember_EmployeeSeveranceMember_SubsequentEventMember" unitRef="USD">300000</us-gaap:SeveranceCosts>
  <bpax:UnpaidCostsAssociatedWithRegisteredDirectOffering decimals="0" contextRef="D2012Q3YTD" unitRef="USD">7933</bpax:UnpaidCostsAssociatedWithRegisteredDirectOffering>
  <bpax:NumberOfCasesConsolidated decimals="INF" contextRef="D2012Q3_M0924_ShareholderDerivativeActionMember" unitRef="Item">2</bpax:NumberOfCasesConsolidated>
  <bpax:NetCashRequiredToObligateEntityToEffectMerger decimals="-6" contextRef="I2012Q3_MinimumMember" unitRef="USD">17000000</bpax:NetCashRequiredToObligateEntityToEffectMerger>
  <bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements contextRef="D2012Q3YTD_MinimumMember">P3Y</bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements>
  <bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements contextRef="D2012Q3YTD_MaximumMember">P5Y</bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements>
  <us-gaap:ProceedsFromCollaborators decimals="-5" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember" unitRef="USD">1000000</us-gaap:ProceedsFromCollaborators>
  <bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable decimals="0" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_ScenarioForecastMember" unitRef="USD">500000</bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable>
  <bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable decimals="0" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember" unitRef="USD">750000</bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable>
  <bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable decimals="0" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember" unitRef="USD">500000</bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable>
  <bpax:NumberOfBusinessDaysConsideredInMilestonePayments decimals="INF" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember" unitRef="Item">5</bpax:NumberOfBusinessDaysConsideredInMilestonePayments>
  <bpax:CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight decimals="-5" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember" unitRef="USD">4000000</bpax:CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight>
  <bpax:NumberOfBusinessDaysConsideredInMilestonePayments decimals="INF" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember" unitRef="Item">5</bpax:NumberOfBusinessDaysConsideredInMilestonePayments>
  <bpax:NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment decimals="INF" contextRef="D2012Q4_M10_MinimumMember_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember" unitRef="Item">180</bpax:NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment>
  <bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales decimals="2" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember" unitRef="Pure">0.05</bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales>
  <bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales decimals="4" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember" unitRef="Pure">0.0750</bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-23852199</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-44959599</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-121791</us-gaap:IncomeTaxExpenseBenefit>
  <bpax:PaymentsToFractionalSharePayout decimals="0" contextRef="D2012Q2_M06" unitRef="USD">658</bpax:PaymentsToFractionalSharePayout>
  <dei:PreEffectiveAmendmentNumber contextRef="D2012Q3YTD">1</dei:PreEffectiveAmendmentNumber>
  <dei:AmendmentDescription contextRef="D2012Q3YTD">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities act of 1933 or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</dei:AmendmentDescription>
</xbrli:xbrl>
